Immunosuppressive dietary n-3 polyunsaturated fatty acids differentially modulate costimulatory regulation of murine CD4+ T-cell function by Ly, Lan H.
  
IMMUNOSUPPRESSIVE DIETARY N-3 POLYUNSATURATED FATTY ACIDS 
DIFFERENTIALLY MODULATE COSTIMULATORY REGULATION OF 
MURINE CD4+ T-CELL FUNCTION 
 
  
A Dissertation 
by 
LAN H. LY 
 
 
Submitted to the Office of Graduate Studies of  
Texas A&M University 
 in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
December 2004 
 
 
Major Subject: Nutrition
 
 
 
 IMMUNOSUPPRESSIVE DIETARY N-3 POLYUNSATURATED FATTY ACIDS 
DIFFERENTIALLY MODULATE COSTIMULATORY REGULATION OF 
MURINE CD4+ T-CELL FUNCTION 
 
A Dissertation 
by 
LAN H. LY 
 
Submitted to Texas A&M University 
 in partial fulfillment of the requirements  
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
Approved as to style and content by: 
_____________________________    ___________________________ 
              Robert S. Chapkin     David N. McMurray 
 (Chair of Committee)                     (Member) 
 
_____________________________    ____________________________ 
     C. Jane Welsh        Vernon L. Tesh 
       (Member)             (Member) 
 
_____________________________    ____________________________ 
 Robert S. Chapkin          John McNeill 
       (Chair of Nutrition Faculty)      (Head of Department) 
 
December 2004 
 
Major Subject: Nutrition
   
 iii
ABSTRACT 
Immunosuppressive Dietary n-3 Polyunsaturated Fatty Acids Differentially Modulate 
Costimulatory Regulation of Murine CD4+ T-cell Function.  (December 2004) 
Lan H. Ly, B.S., University of California, San Diego 
Chair of Advisory Committee:  Dr. Robert S. Chapkin 
 
 
 Consumption of fish oils (FO) enriched with the n-3 polyunsaturated fatty acids 
(PUFA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), is beneficial to 
a variety of inflammatory disorders due, in part, to the alteration of membrane 
composition of T-lymphocytes and other immune cells.  We previously observed that 
down-regulation of proliferation and cytokine synthesis by CD4
+
 T-cells in mice fed diets 
rich in n-3 PUFA was dependent on the involvement of CD28, a co-stimulatory molecule 
necessary for T-cell activation.  Since the co-receptor homologues, CD28 and CTLA-4, 
have opposing effects on T-cell activation, we hypothesized that the balance of 
costimulatory and downregulatory properties of CD28 and CTLA-4, respectively, would 
be altered by diet.  A significant increase (p<0.05) in CD28 and CTLA-4 surface 
expression was observed in CD4+ T-cells post-stimulation with phorbol ester and calcium 
ionophore (PMA/Iono) or anti-CD3 and anti-CD28 (αCD3/CD28) antibodies in all diet 
groups.  A significant increase (p<0.01; 20%) in the number of CD28 molecules was 
observed in n-3 PUFA vs. CO-fed mice after 48 h of in vitro CD4+ T-cell activation, and 
both CTLA-4 mRNA transcript and protein levels were upregulated by 50% at 72 h post-
activation (p<0.01).  Treatment with anti-CTLA-4 mAb in vivo in Mycobacterium bovis 
(BCG)-vaccinated mice did not alter the suppressive effects of dietary n-3 PUFA on 
antigen (PPD)-induced lymphocyte proliferation or delayed hypersensitivity reactions.  
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Ligation of CD28 upregulates IL-10 receptor (IL-10R) expression on CD4+ T-cells.  
Therefore, we hypothesized that dietary n-3 PUFA would suppress T-cell function 
through the effects of IL-10.  Surprisingly, the proliferation of purified splenic CD4+ T-
cells activated in vitro with αCD3/CD28 was suppressed by dietary n-3 PUFA in both 
conventional mice (C57BL/6) and IL-10 gene knockout (IL-10-/-) mice.  Furthermore, IL-
10R cell surface expression was significantly down-regulated on CD4+ T-cells from both 
the C57BL/6 and IL-10-/- mice fed dietary n-3 PUFA after 72 h of in vitro stimulation 
with αCD3/CD28.  CD4+ T-cells from C57BL/6 mice fed DHA produced significantly 
less IFNγ and IL-10, while  CD4+ T-cells from IL-10-/- mice fed dietary n-3 PUFA 
produced significantly more IFNγ compared to the CO-fed group.   
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CHAPTER I 
INTRODUCTION 
Lipids (oils and fatty acids) are indispensable for the growth and survival of all 
organisms.  They are important structural components of membranes and, in many 
organisms, play a crucial role in energy storage.  During the past three decades, the 
interest in some specific animal oils, i.e., the long-chain polyunsaturated fatty acids 
(PUFA) present in fish oils (FO), has increased considerably, due to their beneficial 
health effects (1-6).   
Long-chain PUFA are composed of a long hydrocarbon chain (18 or more carbon 
atoms) and a terminal carboxylate group having two or more double carbon bonds.  They 
are classified according to the position of the first double bond, as counted from the 
methyl terminus.  A so-called ω-3 PUFA has its first double bond at position 3, as 
counted from the methyl terminus.  Other PUFA groups are ω-6 and ω-9, where the first 
double bond is located six and nine carbons from the methyl terminus, respectively.  As a 
synonym of ω, the symbol n is often used to classify PUFA (7).  The most prominent 
examples of dietary n-6 PUFA are linoleic acid (LA; 18:2n-6), γ-linolenic acid (GLA; 
18:3n-6) and arachidonic acid (AA; 20:4n-6).  Examples of dietary n-3 PUFA include α-
linolenic acid (ALNA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3), and 
docosahexaenoic acid (DHA; 22:6n-3).  The most abundant n-3 PUFA ingested with 
vegetable oils, ALNA, is not efficiently converted to EPA or DHA in humans (8).  Both 
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EPA and DHA are primarily found in marine FO (7).  The position of the double bond in  
the fatty acids strongly affects the properties of its derivatives.  For example, eicosanoids 
derived from AA (n-6) have strong inflammatory properties, whereas those produced 
from EPA (n-3) are anti-inflammatory (9-12).   
Evidence for the health benefits of dietary n-3 PUFA intake was derived, in part, 
from epidemiological observations of a very low incidence of chronic inflammatory 
conditions in Eskimos (13).  Studies on the role of n-3 PUFA in inflammatory bowel 
diseases (IBD) started at the end of the 1980s.  McCall et al treated 6 patients with active 
ulcerative colitis (UC) by giving 3-4 g of EPA daily for 12 weeks, which resulted in 
improvement of clinical symptoms and histological appearance, and a decrease in serum 
leukotrienes (LTB4), an eicosanoid mediator (14).  Similarly, other studies continued to 
report these beneficial anti-inflammatory effects of n-3 PUFA (15, 16), as well as to 
demonstrate improvement in all disease activity variables (17, 18) and prolonged 
remission (19, 20).  Recent epidemiological evidence suggests that the increasing 
incidence of Crohn’s Diseases (CD) in Japan is strongly correlated with, among other 
factors, the increasing ratio of n-6: n-3 PUFA intake in the average Japanese diet.  
Increased dietary intake of n-6 PUFA with lower levels of n-3 PUFA may contribute to 
the development of CD (21).  Although some studies report no benefit (22), it has 
recently been shown that increasing dietary n-3 PUFA intake in patients with IBD may 
enhance (by 65%) the absorption and the utilization of saturated fatty acids such as 
palmitic acid, improving overall nutritional status (6).  These data strongly support the 
efficacy of dietary n-3 PUFA in the treatment of patients with IBD or other chronic 
inflammatory conditions.   
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 A variety of molecular mechanisms have been proposed to explain how n-3 
PUFA can modulate inflammation and immune cell function.  Alterations in eicosanoid 
(e.g., prostaglandins (PG), leukotrienes) synthesis have long been regarded as the primary 
anti-inflammatory mechanism of n-3 PUFA.  Eicosanoids are a group of chemical 
messengers that act within the immune system to modulate the intensity and duration of 
inflammatory responses (reviewed in (23-25)).  For example, prostaglandin E2 (PGE2) 
has a number of proinflammatory effects including inducing fever, increasing vascular 
permeability and vasodilation, and enhancing pain and edema caused by other agents 
such as bradykinin and histamine.  These compounds provide a link between PUFA, 
inflammation, and immune function.  Eicosanoids are synthesized from n-6 and n-3 
PUFA, in particular AA, di-homogamma linolenic acid (DGLA), and EPA.  The fatty 
acid precursor for eicosanoid synthesis is released from cell membrane phospholipids by 
the action of phospholipase A2 activated in response to a cellular stimulus.  AA is usually 
the principal precursor for eicosanoid synthesis due to its dominant presence over EPA 
and DGLA in the membranes of immune cells.  Therefore, the ability to produce these 
mediators is strongly influenced by the fatty acid (FA) composition of membrane 
phospholipids.  Increased consumption of FO results in increased proportions of EPA and 
DHA in inflammatory cell phospholipids, partly at the expense of AA (26, 27), thereby 
leaving less substrate for AA-derived eicosanoids.  The reduction in the generation of 
AA-derived mediators that accompany FO consumption has led to the hypothesis that FO 
is anti-inflammatory because it affects PG synthesis (12, 28).  However, it is now 
apparent that the ability of long-chain n-3 PUFA to influence production of eicosanoids 
extends beyond simply decreasing substrate availability.  For example, EPA competively 
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inhibited the metabolism of AA by cyclooxygenase enzyme-2 (COX-2), thereby reducing 
the generation of 2-series PG and thromboxanes (TX) (29).  Furthermore, n-3 PUFA 
were able to act as a substrate for COX, giving rise to derivatives that differ in structure 
from those produced from AA (i.e., 3-series PG).  Therefore, the n-3 PUFA-induced 
suppression in the production of AA-derived eicosanoids may be accompanied by an 
elevation in the production of n-3 PUFA-derived eicosanoids (27, 30).  Consistent with 
these results, PGE2 concentrations in the medium taken from lymphocytes cultured in the 
presence of a range of different fatty acids did not correlate with the inhibitory effects of 
the fatty acids upon proliferation (31).  Moreover, indomethacin, a COX inhibitor, did not 
reverse the anti-proliferative effects of the fatty acids (32).  These observations provide 
convincing evidence that the immunosuppressive effects of dietary n-3 PUFA are 
independent of the production of eicosanoids.   
In order to maintain their integrity, cells are surrounded by a plasma membrane 
composed of fatty molecules.  Molecules that make up the membrane have two long fatty 
acid chains with a head group that is H2O-soluble by virtue of being electrically charged, 
making them amphipathic.  Thus, membranes are formed because these bipartite 
molecules, called phospholipids, spontaneously orient themselves to form a double layer, 
or bilayer, with their fatty chains facing inward and their water-seeking head groups 
facing outward.  The membrane is given rigidity by the interspersion of cholesterol, 
which helps stabilize the outer membrane of all cells.  Carbohydrates, covalently bound 
either to proteins as constituents of glycoproteins or to lipids as constituents of 
glycolipids, also help stabilize the conformation of many membrane proteins.  
Sphingolipids, phospholipids that bear a sphingosine instead of a glycerol backbone, and 
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cholesterol interact to help cluster proteins into regions called microdomains.  These 
microdomains function as “rafts” or platforms for the partitioning of proteins that are 
critical for signal transduction (33, 34).  By their distinct lipid composition, lipid rafts 
concentrate lipid-modified signaling proteins within the plane of the plasma membrane to 
facilitate signal transduction and cellular response.  The importance of membrane rafts in 
immune cells will be discussed further in subsequent paragraphs. 
T-cells are lymphocytes which develop in the thymus.  They can be divided into 
two subpopulations, CD4+ or CD8+, both of which express a T-cell receptor (TCR) 
associated with a complex of transmembrane signaling proteins called CD3 (35).  Cell-
mediated immunity is the effector function of T-lymphocytes, which serves as an 
important defense mechanism against many microbes.  The CD4+ T-cells differentiate 
into helper T-cells (Th), while the CD8+ T-cells differentiate into cytotoxic T-cells 
(CTL), each performing very different effector functions in the immune system.  Two 
different subsets of Th-cells activate macrophages (Th1) or promote B-cell antibody 
production (Th2), whereas CTLs recognize and kill host cells infected with viruses or 
other intracellular microbes (36).  Despite their various effector functions following 
differentiation, all naïve T-cells require at least two distinct extracellular signals to induce 
their proliferation and transformation into effector cells.  The first signal originates from 
the ligation of the TCR complex and its co-receptors (e.g., CD4 or CD8) with a specific 
major histocompatibility complex (MHC)-peptide complex.  The second signal is 
dependent upon the ligation of cell surface molecules that provide essential costimulatory 
signals which are complementary to the TCR engagement (37).   
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 The immune system has developed powerful mechanisms to prevent unnecessary 
activation of T-cells and thus either autoimmunity, i.e., a state of responsiveness to self 
antigens, or hypersensitivity, i.e., the prolonged and intense state of responsiveness to 
foreign antigens.  One such mechanism is the intricate balance between positive and 
negative costimulatory signals delivered to T-cells after antigenic counter (38).  Positive 
costimulatory signals are pivotal in determining whether recognition of antigen by T-cells 
leads to full T-cell activation or to anergy/death.  CD28 is the principal co-receptor, 
which is expressed on more than 90% of CD4+ and 50% of CD8+ naïve T-cells (39) and 
provides the second signal.  Although it is constitutively expressed prior to T-cell 
activation, it is well documented that CD28 expression is regulated following TCR 
engagement with the MHC-peptide complex (40, 41).  The intracellular signal cascade 
generated upon CD28 ligation with CD80 (also known as B7-1) and CD86 (B7-2), which 
are expressed on activated antigen presenting cells (APC), acts in concert with signals 
from the TCR complex to fully activate the T-cells.  The CD28 costimulatory activity has 
been demonstrated in vitro and in vivo by antibody cross-linking and blocking 
experiments in normal mice and in CD28-deficient mice (42). 
In addition, recent findings indicate that regulation of immune responses may be 
achieved by the expression of inhibitory costimulatory molecules on APC and peripheral 
tissues that mediate negative costimulatory signals to the T-cell (42, 43).  The most 
prominent inhibitory receptor is cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), 
a homolog of CD28.  Expressed only on activated T-cells, CTLA-4 binds to the same 
ligands as CD28, albeit with much higher affinity, thereby leading to the termination of 
the immune response (44).  In both human (45) and murine (44) systems, cell surface 
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expression of CTLA-4 peaks 48 h after activation, returning to background levels by 96 
h.  Thus, the period of time in which CD28 is transiently downregulated and less 
responsive to signaling is the time period during which CTLA-4 expression is maximal, 
suggesting that CTLA-4 may be functionally active at a time when CD28 function has 
waned.  Studies have shown that ligation of CTLA-4 inhibits T-cell activation by 
reducing IL-2 production and IL-2 receptor expression, and by arresting T-cells at the G1 
phase of the cell cycle (44, 46).   
An increasing body of evidence indicates that T-cell activation involves the lateral 
migration of many molecules associated with TCR-mediated signaling.  When T-cells are 
stimulated with planar lipid bilayers or APC possessing antigenic peptide-MHC, a highly 
ordered macromolecular interface, termed the immunological synapse (IS), forms 
between the T-cell and the APC surface (47).  The formation of an IS correlates with the 
clustering of glycolipid-enriched microdomains known as lipid rafts which were 
introduced earlier.  By their distinct lipid composition, lipid rafts concentrate lipid-
modified proteins within the plane of the plasma membrane.  At the exoplasmic face, 
proteins attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) 
anchor are almost exclusively found in rafts, whereas acylated proteins are found at the 
cytoplasmic face of rafts.  Many proteins involved in signal transduction are modified by 
acyl moieties to be attached to the plasma membrane and/or concentrated into lipid rafts 
(48).  For example, Src-family kinases such as Lck and Fyn are acylated at the N-
terminus by myristoyl (14:0) and palmitoyl (16:0) moieties (reviewed in (49)).  The IS is 
composed of a central core containing the TCR, protein kinase C θ (PKCθ), Lck, Fyn, 
and CD28, surrounded by a ring enriched with adhesion molecules (i.e., LFA-1, CD43) 
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(50-52).  As mentioned previously, lipid rafts are enriched with signaling molecules 
critical for TCR-mediated signaling such as Lck, linker for activation of T-cells (LAT), 
and PKCθ and their biological integrity is essential for proper TCR-mediated signaling 
(53-55). 
It has been demonstrated by us (56-58) and others (59, 60) that dietary n-3 PUFA 
affect raft composition and function on T-cells through an eicosanoid-independent 
mechanism.  Treatment of lipid rafts from Jurkat T-cells with EPA markedly displaced 
Lck and Fyn content, thereby reducing subsequent downstream signaling events (61).  
Similary, we have recently demonstrated that dietary DHA suppressed PKCθ recruitment 
to lipid rafts in murine T-lymphocytes (62).  In contrast, the GPI-anchored proteins, 
CD59 and CD48, the ganglioside GM1, and caveolin remain in rafts after dietary n-3 
PUFA enrichment (63).  Protein displacement from lipid rafts could be due to altered 
protein acylation or changes in raft lipid composition.  These studies illustrate that diet n-
3 PUFA-mediated changes in membrane composition, as well as protein acylation, are 
likely to have a broad impact on lymphocyte signaling pathways (57). 
Immediately following stimulation, lymphocytes begin to transcribe genes that 
were previously silent to synthesize a variety of new proteins.  These proteins include 
secreted cytokines (in T-cells), which stimulate the growth and differentiation of the 
lymphocytes themselves and of other effector cells, and cytokine receptors, which make 
lymphocytes more responsive to cytokines.  As the principal mediators of communication 
between lymphocytes, cytokines play a critical role in mediating inflammatory and 
immune responses. 
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Although it is important for the immune system to mount a proper response to any 
foreign invader, it is even more important to inhibit it in a timely manner.  An over-
exaggerated response is potentially detrimental for the host immune system itself and to 
other tissues.  Several mechanisms are involved in regulating and balancing immune and 
inflammatory responses.  These include cytokines possessing anti-inflammatory, 
immunosuppressive activities such as interleukin-10 (IL-10) (reviewed in (64)).  IL-10 
limits and ultimately terminates inflammation by adjusting the intensity of the immune 
and inflammatory responses to the severity of destruction caused by a pathological 
condition or pathogen.  In addition, IL-10 regulates growth and death of B-cells, natural 
killer (NK) cells, cytotoxic and helper T-cells, mast cells, granulocytes, dendritic cells, 
keratinocytes, and endothelial cells.  IL-10 also plays a key role in the differentiation and 
function of the T-regulatory cell, which may assist prominently in the control of immune 
responses and tolerance in vivo (65).   
As a mechanism of maintaining immunologic tolerance to self antigens, IL-10 
induces T-cell anergy, a state of immune inactivation characterized by abolished 
proliferative and cytokine responses.  It was recently demonstrated that the unresponsive 
state of murine T-cells which had been tolerized by IL-10, was reversed by anti-CD3 
monoclonal antibody (mAb) stimulation and IL-2, a growth-promoting cytokine, but not 
by anti-CD28 mAb stimulation (66).  IL-10 inhibited tyrosine phosphorylation of CD28, 
thereby blocking its binding to phosphatidylinositol-3 kinase (PI3K).  Furthermore, CD28 
stimulation significantly enhanced IL-10 receptor (IL-10R) expression after 24 h in vitro 
activation.  Together, these results demonstrate that the suppressive effects of IL-10 
involve direct action on the CD28 co-stimulatory pathway.  In turn, CD28 ligation 
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upregulates IL-10R expression, rendering the T-cell more susceptible to IL-10 
suppression (67).   
The beneficial anti-inflammatory effects of dietary n-3 PUFA can be attributed, in 
part, to suppressed production of pro-inflammatory cytokines (TNFα, IL-1β, and IL-6) 
(68) and decreased expression of adhesion molecules (e.g. ICAM-1, VCAM-1) as shown 
in both animal and human studies (69, 70).  These effects also occur at the level of altered 
gene expression.  Recent studies have shown that n-3 PUFA can down-regulate the 
activity of the nuclear transcription factor nuclear factor kappa B (NFκB) (71), which 
plays a role in inducing a range of inflammatory genes, including COX-2, ICAM-1, 
VCAM-1, TNFα, IL-1β, and IL-6, in response to inflammatory stimuli (72).  
Animal feeding studies have shown that diets enriched with EPA and DHA 
decreased ex vivo production of TNFα, IL-1β, and IL-6 by rodent macrophages (73) and 
monocytes (74).  Feeding fish oil decreased the level of MHC II (75) and IFNγ receptor 
expression (76) on murine peritoneal macrophages and diminished ex vivo presentation 
of antigen (keyhole limpet hemocyanin: KLH) by spleen cells (77).  These studies 
suggest that dietary fish oil might impair the cell-mediated immune response by 
decreasing the activity of antigen-presenting cells and by decreasing the sensitivity of 
macrophages to T lymphocyte-derived cytokines.  
Experiments conducted by us and others revealed that fish oil decreases NK cell 
activity, cytotoxic T lymphocyte activity (78), expression of the high affinity IL-2 
receptor alpha gene in activated lymphocytes (5), lymphocyte proliferation, and the 
production of IL-2 (10).  Addition of either EPA or DHA to the diet of mice consuming a 
safflower oil diet (devoid of n-3 PUFA) decreased the delayed-type hypersensitivity 
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(DTH) response to tuberculin in mice vaccinated with Mycobacterium bovis BCG (3). 
These results suggest that fish oil may impair cell-mediated immunity, and could play a 
role in the prevention and/or therapy of chronic inflammatory diseases characterized by a 
dysregulated CD4+ T-cell response which drives the production of pro-inflammatory 
cytokines and eicosanoids.   
Animal feeding studies have often used large amounts of FO, i.e., a diet in which 
FO contributes 20% by weight will mean that DHA plus EPA comprise up to 30% of 
dietary fatty acids (79).  We and others have demonstrated that diets containing relatively 
low levels of dietary n-3 PUFA [EPA or DHA at a level of 18% of total fatty acids or less 
(~45% of total calories)] have similar effects to whole FO (3, 9, 10, 80) using a short-
term feeding paradigm.  The hypothesis that the active constituents of FO, namely DHA 
and EPA, have similar effects on the immune response has been supported by some 
studies (81-83) and rejected by others (84-86).   
 Mice are the mainstay of in vivo immunological experimentation and, in many 
respects, they mirror human biology remarkably well (reviewed in (87)).  This 
conservation of function is reflected in recent reports on the sequencing of both human 
and mouse genomes, which reveal that, to date, 99% of mouse genes are homologous to 
human genes (88).  We and others have continued to successfully use the mouse model to 
elucidate the effect of dietary n-3 PUFA on T-cell functions (3, 10, 56, 58, 78, 89).  
Moreover, the murine model has been used extensively to study T-cell activation (90, 
91), intracellular signaling pathways (92-94), and cytokine profiles (95, 96) in murine 
splenocytes.  Although caution needs to be taken in extrapolating data obtained in mice to 
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humans, mice will continue to be absolutely essential for continued progress in our 
understanding of the immune response in health and disease (87, 97).   
There is mounting evidence that CD4+ and CD8+ T-cells are affected 
differentially by diet in their immunologic responses (98, 99).  Many studies report n-3 
PUFA-mediated effects on whole splenocyte cultures and few have addressed the role of 
n-3 PUFA on T-cell subset regulation.  Our laboratory has demonstrated that these T-cell 
subsets are affected differentially by various dietary components.  Feeding dietary DHA 
to mice reduced the proportion of splenic CD8+ T-cells, but not CD4+ T-cells (9).  
Moreover, dietary n-3 PUFA principally modulated the function of CD4+ T-lymphocyte 
subsets specifically by suppressing the function of CD4+ Th1 cells which were polarized 
in vitro with a particular agonist set [phorbol-12-myristate-13-acetate (PMA) and a 
calcium ionophore, Ionomycin (Iono)] without affecting or even enhancing the function 
of CD4+ Th2 cells (10).  Enhanced activation induced cell death (AICD) or apoptosis in 
CD4+ Th1 polarized cells was also seen in mice fed FO, which agrees with the previous 
data (100).  Thus, we have chosen to further elucidate the effects of dietary n-3 PUFA on 
purified murine splenic CD4+ T-cells.   
 The effect of dietary n-3 PUFA on T-cell function appears to be dependent upon 
the in vitro stimuli used in culture.  In earlier studies, it was clearly demonstrated that the 
selective dietary effects of n-3 PUFA on CD4+ T-cells was dependent upon ligation of the 
co-stimulatory molecule, CD28, whose activation is required in addition to the T-cell 
receptor/CD3 (TCR/CD3) complex to induce a functional response for proper T-cell 
propagation (4).  Ligation of CD28 is known to upregulate CTLA-4 and IL-10R 
expression, either or both of which may be responsible for suppression of T-cell 
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proliferation and/or cytokine production (67, 89).  Therefore, to determine the precise 
role CD28 plays in diet-mediated immunosuppression, we examined the influence of 
dietary n-3 PUFA on CD28, CTLA-4, and IL-10R protein expression on the surface of 
purified CD4+ T-cells cultured in vitro with antibodies to anti-CD3 and anti-CD28 
(αCD3/αCD28).  In studies where we examined the CD28 receptor protein itself, 
activation with the PMA/Iono stimuli was used to bypass the membrane receptors.  In 
addition, we proceeded to investigate the role of the suppressive IL-10 cytokine, in the 
context of CD28, in IL-10 gene knockout mice fed dietary DHA or EPA.  Our overall 
hypothesis was that dietary n-3 PUFA would alter the regulation or function of certain T-
cell protein receptors and/or modulate the interplay between CD28, CTLA-4, and IL-10. 
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CHAPTER II 
DIETARY N-3 POLYUNSATURATED FATTY ACIDS 
MODULATE  THE BALANCE BETWEEN CD28 AND CTLA-4 EXPRESSION 
ON MURINE CD4+ T-CELLS 
Introduction 
 Activation of T-lymphocytes is thought to require at least two signals, one 
delivered by the T-cell receptor (TcR) complex after antigen (Ag) recognition, and one 
provided on engagement of co-stimulatory receptors, such as CD28.  Upon interaction 
with its ligands B7.1 (CD80) and/or B7.2 (CD86), CD28 transduces a signal which 
enhances T-cell proliferation and cytokine secretion, and sustains the T-cell response 
(101-103).  Conversely, the CD28 homologue cytotoxic T-lymphocyte-associated antigen 
4 (CTLA-4) (CD152) inhibits T-cell responses by reducing IL-2 production and IL-2 
receptor expression, and by arresting T-cells at the G1 phase of cell cycle (89, 104).  Both 
B7 ligands bind to CD28 and CTLA-4, but they differ in their binding affinity, structure 
and temporal expression (105).  CTLA-4 reportedly binds B7 with a 20-fold higher 
affinity than CD28 (106, 107) and thereby aids in the termination of immune responses 
(108-110).   
 Others have shown that blockage of CTLA-4 signals prolong T-cell activation and 
expansion both in vitro (44) and in vivo (111, 112). The importance of CTLA-4 as a 
regulator of lymphocyte homeostasis was confirmed by the generation of CTLA-4 
deficient mice, whose development of a lymphoproliferative disorder and severe 
autoimmune disease results in death by 4-5 wk of age.  When restimulated in vitro,  T-
cells from these mice secrete high levels of IL-4 and IFNγ, consistent with a role for 
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CTLA-4 in the regulation of T-cell differentiation (113, 114).  Furthermore, anti-CTLA-4 
treatment exacerbates autoimmune disease in a murine model of multiple sclerosis (115).  
Thus, CTLA-4 is likely to play a critical role in the regulation of many aspects of the T-
cell response. 
 The interplay between CD28 and CTLA-4 has become more evident and more 
complex.  An increasing body of evidence indicates that T-cell activation involves lateral 
migration of many molecules associated with TcR-mediated signaling to form the 
immunological synapse (IS).  Functional and imaging experiments suggest that 
membrane microdomains, termed detergent-insoluble glycosphingolipid-enriched 
domains (or “rafts”), may play an important role in forming the structure of the IS.  It has 
been shown that the recruitment of lipid rafts to the IS is highly dependent on CD28 
costimulation (116).  Furthermore, CTLA-4 localization to the raft is necessary for 
CTLA-mediated negative signaling (117).  The physiological relevance of lipid raft-
associated CTLA-4, however, is currently unknown.  Interestingly, cell surface 
accumulation of CTLA-4 is regulated by its rapid endocytosis (104) suggesting that much 
of the “bioavailable” CTLA-4 may be intracellular.   
 Previous results from our laboratory show that T-lymphocytes from mice fed the 
n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA; 20:5) and 
docosahexaenoic acid (DHA; 22:6), found in fish oil (FO) produced significantly less   
IL-2, but only when cells were activated with αCD3/CD28 and not when activated with 
αCD3/PMA (phorbol ester) (4).  Since CD28 ligation is essential for the rearrangement 
of lipid rafts at the IS (118), dietary n-3 PUFA may alter the ability of CD28 to trigger 
this event and/or modulate signal-transducing proteins that associate to the rafts upon T-
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cell activation.  Our laboratory recently demonstrated for the first time that dietary n-3 
PUFA differentially modulate T-cell raft and non-raft membrane phospholipid and fatty 
acyl composition in vivo (56).  Furthermore, we found that dietary n-3 PUFA feeding 
suppressed partitioning of the signaling molecule, PKCθ, into lipid rafts which was 
associated with a reduction in AP-1 and NF-κB activation (62).  These results suggest 
that by altering the raft membrane composition, diet may influence signaling complexes 
and modulate T-cell activation, thereby, altering the raft function/dynamics which affect 
the opposing costimulatory molecules, CD28 and CTLA-4.   
 On this background, we hypothesized that the balance of costimulatory and 
downregulatory properties of CD28 and CTLA-4, respectively, would be altered by diet.  
To investigate this hypothesis, we have determined the influence of dietary DHA and 
EPA on the regulation of both CD28 and CTLA-4 mRNA and cell surface expression in 
purified murine CD4+ T-cells.  Surprisingly, dietary n-3 PUFA feeding significantly 
upregulated both CD28 and CTLA-4 cell surface protein expression.  However, the levels 
of CD28 mRNA expression were markedly reduced, while CTLA-4 transcript levels were 
enhanced.  The role of the CTLA-4 molecule in diet-mediated immunosuppression was 
studied in vivo using anti-CTLA-4 treatment.  CTLA-4 blockade in vivo in 
Mycobacterium bovis (BCG)-vaccinated mice fed dietary n-3 PUFA did not alter the 
suppressive effects of diet.  Therefore, we demonstrate that dietary n-3 PUFA may 
downregulate T-cell function by altering co-receptor regulation. 
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Materials and Methods 
Diet and animals 
Female, pathogen-free young (12-14g) C57BL/6 mice purchased from Frederick 
National Cancer Research Facility (Frederick, MD) were assigned to one of three semi-
purified diets: 5% corn oil (CO) (control diet containing no n-3 PUFA), 1% DHA + 4% 
CO (DHA), or 1% EPA + 4% CO (EPA), for 14 days.  Diets were analyzed by gas 
chromatography prior to feeding, aliquoted, and stored at -80°C.  Fresh diet was provided 
daily to prevent lipid peroxidation.  There was no significant difference in food intake 
between dietary groups and weight gain was similar in all groups (data not shown).  The 
purified diets met National Research Council nutrition requirements and varied only in 
lipid composition as previously described (3, 10).  The vitamin E levels in the diets were 
approximately equal (mean ± SEM=169.2 ± 4.4 mg/kg diet) and exceeded the minimum 
requirement (22 mg Vitamin E/kg diet).  DHA (88.9% as 22:6, n-3) and EPA (94.1% as 
20:5, n-3) were obtained in ethyl ester form from Martek Biosciences (Columbia, 
Maryland) and Laxdale Ltd (United Kingdom), respectively.  Corn Oil (57.3% as 18:2, n-
6) was obtained from Degussa Bioactives (Champaign, IL) (4).  
 
Measurement of fatty acid composition from mouse sera 
Sera were obtained from mice after 14 d of feeding the three experimental diets.  
Fatty acid methyl esters were extracted using hexane and 0.1 M potassium chloride and 
analyzed by capillary gas chromatography as previously described (56). 
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Isolation and preparation of splenic lymphocytes 
Mice were killed by CO2 asphyxiation.  Spleens were placed in RPMI-complete 
medium [RPMI 1640 with 25 mmol/L HEPES (Irvine Scientific, Santa Ana, CA) 
supplemented with 10% fetal bovine serum (FBS; Irvine Scientific) or 2.5% FBS + 2.5% 
homologous mouse serum (HMS) (58), 1 x 105 u/L penicillin and 100 mg/L streptomycin 
(Irvine Scientific), 2 mmol/L L-glutamine and 10 µmol/L 2-mercaptoethanol].  Spleens 
were dispersed with glass homogenizers and passed through a 149-µm wire mesh filter to 
create single-cell suspensions.  Cells were subsequently washed with RPMI-complete 
medium before T-cell enrichment as previously described (10). 
 
CD4+ T-cell purification 
Total lymphocytes were initially enriched by density gradient centrifugation using 
Lympholyte-M (Cedarlane, Canada) in accordance with the manufacturer’s protocol.  
The resulting cell fraction from each spleen was incubated with an antibody cocktail 
provided by the manufacturer, loaded onto a negative-selection mouse CD4 T-cell 
purification column (R&D Systems, Minneapolis, MN), and incubated for 10 min at 
room temperature (RT).  Non-adherent cells were eluted for purity and viability analysis, 
proliferation, FACS analysis, and real-time PCR assays.  The purity of the CD4 T-cell 
population was analyzed by flow cytometry (FACSCalibur; Becton-Dickinson, Bedford, 
MA) using anti-CD4 antibody conjugated to fluorescein isothiocyanate (Pharmingen, San 
Diego, CA) and determined to be 90.3 ± 1.4% (n=3) (10). 
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T-cell proliferation 
Purified CD4+ T-cells were cultured at 2 x 105 cells per well (200 µl total) in 96-
well round-bottomed microtiter plates (Falcon, Becton-Dickinson).  Cells were cultured 
in the presence of 1 µg/ml plate-bound purified hamster anti-mouse CD3 monoclonal 
antibody (BD Pharmingen) alone, or with 5 µg/ml soluble purified hamster anti-mouse 
CD28 monoclonal antibody (BD Pharmingen).  These concentrations were determined by 
preliminary experiments to induce proliferation without compromising viability (data not 
shown).  For the in vivo anti-CTLA-4 antibody treatment study, whole splenocytes or 
inguinal lymph node cells were stimulated with 2.5 µg/ml of the polyclonal T-cell 
mitogen ConA (Sigma) or 10, 20, or 40 µg/ml of mycobacterial purified protein 
derivative (PPD; Statens Seruminstitut, Copenhagen, Denmark).  Cells were incubated at 
37°C in an atmosphere of 5% CO2 in air for 72 or 96 h.  For the final 6 h, 1.0 µCi [3H]-
thymidine/well (New England Nuclear, North Bellerica, MA) was added to the cultures.  
Cells were harvested on a 96-well cell harvester (Packard Instrument Co.) and cellular 
thymidine uptake was measured using a liquid scintillation counter (Beckman Coulter).  
Results are expressed as net disintegrations per minute (DPM).    
 
T-cell activation for flow cytometry and real-time RT-PCR 
Purified CD4+ T-cells were cultured at 1-5 x 106 cells per well (2 ml total volume) 
in 24-well flat-bottomed microtiter plates (Falcon, Becton-Dickinson).  Cells were 
cultured in the presence of 1 ng/ml PMA with 500 nM Ionomycin (Calbiochem-
Novabiochem, San Diego, CA) or 1 µg/ml anti-CD3 with 5 µg/ml anti-CD28 (BD 
Pharmingen) at 37°C in an atmosphere of 5% CO2 in air for the indicated times (4).   
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Immunofluorescence flow cytometry 
For quantitative surface receptor staining, 106 CD4+ T-cells from activated and 
control cultures were first incubated for 10 min at RT with 0.5 µg/ml CD16/32 Ab (BD 
Pharmingen) to block Fc receptors.  The addition of 7-aminoactinomycin D (7-AAD, 
Sigma) at 1 µg/ml for 10 min allowed for the exclusion of dead cells.  Cells were then 
incubated with anti-CD28 or anti-CTLA-4-phycoerytherin (PE, red) (BD Pharmingen) 
labeled mAb diluted to 4 µg/ml in 0.5% BSA solution for 30 min.  Samples were washed 
to remove unbound antibody before flow cytometric analysis.  The cells were analyzed 
on a FACSCalibur (Becton-Dickinson Immunocytometry Systems, San Jose, CA) flow 
cytometer, using CellQuest (Becton-Dickinson) acquisition software.  Phycoerythrin 
fluorescence was collected through the 585/42 nm bandpass filter, and 7-AAD 
fluorescence was collected through the 670 nm long pass filter.  List mode data were 
acquired on a minimum of 10,000 events defined by light scatter gates.  Surface protein 
expression was quantified using QuantiBrite PE Beads (Becton-Dickinson) conjugated 
with 4 levels of PE.  Data analysis was performed in CellQuest/FlowJo (Treestar, Inc., 
Ashland, OR), using forward and side light scatter to gate on the lymphocyte population 
and 7-AAD fluorescence to exclude non-viable cells from analysis.  The Calibration 
Platform in FlowJo was used to convert the fluorescence intensity scale into absolute 
number of PE molecules.  For each sample stained with a mAb, the median fluorescence 
intensity, expressed as the equivalent number of PE molecules, was determined to be the 
median antibody binding capacity (ABC) for the cell population.  By using a known ratio 
of PE to antibodies (1:1), PE molecules per cell were then converted to antibodies per cell 
or antibody binding capacity (ABC) (119).   
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For intracellular (total) detection of CTLA-4, purified splenic CD4+ T-cells were first 
incubated with CD16/32 Ab as described above, fixed in 1% paraformaldehyde at 4°C 
(Electron Microscopy Sciences) and stained with anti-CTLA-4 mAb at 4°C in the 
presence of 0.03% saponin.  Cells were then extensively washed in 0.03% saponin and 
1% BSA solution before analysis by flow cytometry (119). 
 
Real-time RT-PCR 
T-cell RNA was isolated using RNAqueous Total RNA kit (Ambion) according to 
the manufacturer’s protocol.  Total RNA was quantified using a RiboGreen RNA 
Quantitation Kit (Molecular Probes).  Real time PCR was performed using the ABI 7700 
(Applied Biosystems) and Taqman Probes as described previously (120).  Probes and 
primers for CD28 and CTLA-4 mouse genes were designed by Primer Express software, 
version 1.7. Primer and probe sequences were then checked for sequence homology 
against known genes using a BLAST search (http://www.ncbi.nlm.nih.gov/blast).  All 
data were normalized to 18S rRNA expression. 
 
In vitro treatment with anti-CTLA-4 mAb 
Mouse splenic CD4+ T-cells were cultured for cell proliferation as described 
above with the addition of 100 µg/ml purified mAb anti-CTLA-4 (clone UC10-4F10; BD 
Pharmingen) or isotype hamster IgG control (BD Pharmingen). 
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In vivo treatment with anti-CTLA-4 mAb 
UC10-4F10 (hamster anti-murine CTLA-4) hybridoma cells were obtained from 
ATCC (HB-304).  The high titered supernatant was purified over HiTrap protein G 
columns (Pharmacia) and acid eluted as per the manufacturer’s protocol.  Extracts were 
then dialyzed with 1X PBS overnight at 4°C using Slide-A-Lyzer cassettes (Pierce, 
Rockford , IL).  Antibody was subsequently concentrated using Amicon Ultra Centrifugal 
Filter Devices (Millipore).  The specificity of the Ab was checked by Western blotting 
using recombinant CTLA-4 protein (BD Pharmingen) and the bioactivity was determined 
by measuring whole splenocyte proliferation in the presence of purified Ab and anti-CD3 
(44).  The purified CTLA-4 Ab was stored at -80°C prior to use.  Modulation of CTLA-4 
function in vivo was accomplished by the daily intraperitoneal injection of 100 µg/mouse 
of purified mAb anti-CTLA-4 in 100 µl PBS or affinity purified hamster IgG (Cappel 
Research Products, Durham, NC) as a negative control for the 5 d prior to sacrifice.   
 
Immunization and footpad testing 
Mice were immunized with approximately 106 viable Mycobacterium bovis 
(BCG) organisms (Danish 1331; Statens Seruminstitut, Copenhagen, Denmark) by 
subcutaneous injection 6 wks prior to sacrifice to allow an Ag-specific immune response 
to develop.  Diets were initiated 14 d before the end of the 6 wk vaccination period as 
previously described (3).  Testing with 0.05 ml of purified protein derivative (PPD) 
containing 100 tuberculin units was performed by intradermal injection into both hind 
footpads 3 d prior to sacrifice to determine the degree of antigen-specific delayed-type 
hypersensitivity (DTH).  Footpad swelling was quantified with microcalipers and 
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compared to preinjection footpad thickness in millimeters according to our previously 
published protocol (3).   
 
Statistical analysis 
Data were analyzed using two-way ANOVA for main treatment effects using 
SuperANOVA statistical software (Berkeley, CA).  A difference between means was 
tested using Duncan’s multiple range test.  Significant and highly significant differences 
were defined as p<0.05 and p<0.01, respectively, for all tests.   
 
Results  
Dietary n-3 PUFA suppress splenic CD4+ T-cell proliferation 
 Previous results from our laboratory suggested that reduced IL-2 cytokine 
production of CD4+ T-cells in mice fed diets rich in n-3 PUFA was highly dependent on 
the involvement of the co-stimulatory molecule, CD28 (4).  To define the ability of DHA 
and EPA to modulate CD4+ T-cell function, CD4+ T-cells purified from the spleens of 
mice fed 5% (w/w) corn oil (CO; control diet containing n-6 PUFA), 1% DHA, or 1% 
EPA were stimulated for 72 h and subsequently pulsed with 3H-[TdR].  Fig. 1A illustrates 
that both experimental diets significantly reduced CD4+ T-cell proliferation when 
cultured with anti-CD3 and anti-CD28 in the presence of 10% FBS (p<0.01).  Due to the  
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length of time in culture, a parallel set of cultures were maintained in diet-matched 
homologous mouse serum (HMS) to prevent the loss of cell membrane fatty acids as we 
and others have previously reported (58, 121, 122).  Fig.1B demonstrates that 
maintaining the T-cell lipid environment in vitro by the addition of HMS sustained the in 
vivo modifications induced by diet.  The suppressive effect of dietary n-3 PUFA on 
proliferation was significantly enhanced in the presence of HMS.  We recently reported 
that diet markedly alters the fatty acid composition of sera collected from mice fed 
control and experimental diets (58).  Table 1 shows that FBS was relatively devoid of n-3 
PUFA (20:5n-3, 22:5n-3, 22:6n-3) whereas mouse sera from DHA- and EPA-fed mice 
was highly enriched in 22:6n-3 and 20:5n-3, respectively.  Therefore, most of the in vitro 
experiments presented below were performed using HMS.   
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TABLE I.  Fatty acid composition of sera used for cell culture. 
 
Fatty Acid FBS MS-CO MS-DHA MS-EPA
16:0 1.71 ± 0.02 14.20 ± 0.55
18:0 0.80 ± 0.02 7.93 ± 0.20
18:1n-9/n-7 1.63 ± 0.05 15.54 ± 0.22
18:2n-6 0.42 ± 0.01 17.72 ± 0.37 9.96 ± 0.46 7.04 ± 0.56
20:4n-6 0.53 ± 0.01 12.32 ± 0.61 1.72 ± 0.36 1.67 ± 0.15
20:5n-3 tr tr 2.07 ± 0.28 5.64 ± 0.44
22:5n-3 0.15 ± 0.00 tr tr 0.49 ± 0.01
22:6n-3 0.17 ± 0.01 2.24 ± 0.24 5.51 ± 0.65 2.40 ± 0.26
10.24 ± 0.62 10.36 ± 0.42
4.78 ± 0.112.56 ± 0.42
11.36 ± 0.21 13.65 ± 0.55
Mouse serum from CO, DHA, and EPA-fed mice were extracted and analyzed to assess 
fatty acid composition.  FBS is shown for comparison. Values are expressed as mg fatty 
acid/ml serum and represent means ± SEM, n=3.  FBS, fetal bovine serum; MS-CO, 
serum from corn oil fed mice; MS-DHA, serum from DHA fed mice; MS-EPA, serum 
from EPA fed mice; tr, trace amount (<0.1 mg/ml).   
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FIGURE 1.   Dietary DHA and EPA down-regulate murine CD4+ T-cell proliferation.  Purified splenic CD4+ T-cells 
from mice fed CO, DHA, or EPA were activated with antibodies to surface receptors CD3 and CD28 and cellular 
uptake of [3H]-thymidine was measured 72 h post-activation.  Results are expressed as mean ± SEM of the net 
disintegrations per minute (DPM), n=7.  Different letters denote highly significant differences found between diet 
groups (p<0.01).  A: cells cultured in the presence of 10% FBS; B: cells cultured in the presence of 2.5% homologous 
mouse serum (HMS) + 2.5% FBS.   
Dietary n-3 PUFA enhance surface expression of CD28 on CD4+ T-cells  
 We initiated experiments to define the role of the co-stimulatory receptor CD28 in 
diet-mediated immunosuppression.  As shown in Fig. 2A, activation of CD4+ T-cells with 
phorbol ester (PMA) and calcium ionophore (Iono) rapidly upregulated cell surface 
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protein expression of CD28 with levels peaking at 48 h post-activation.  Cells from mice 
fed DHA had significantly higher levels (20%) of CD28 molecules on a per-cell basis 
than those fed the CO (control) diet after 48 h of in vitro stimulation (p<0.01; Fig. 2A 
Inset).  These results were contrary to our hypothesis that dietary n-3 PUFA would 
reduce the levels of CD28 protein present on the cell surface, thereby leading to reduced 
cell proliferation and cytokine production (5, 10).  Real-time PCR analysis (Fig. 2B) 
indicated that dietary n-3 PUFA markedly reduced levels of CD28 mRNA expression at 
t=0 and 24 h post-activation with PMA/Iono when compared to the CO diet (p<0.05).  
Following 72 h activation, all diet groups approached maximum mRNA expression levels 
with no significant differences found. 
 
Dietary n-3 PUFA enhance both CTLA-4 protein (total and surface) and mRNA 
transcript levels on CD4+ T-cells 
It has been reported that cell surface accumulation of CTLA-4 is primarily 
regulated by its rapid endocytosis (104).  Indeed, flow cytometric analyses revealed that 
the majority of CTLA-4 protein accumulated intracellularly (total) at all time points 
following CD4+ T-cell activation with anti-CD3 and anti-CD28 when compared to cell  
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FIGURE 2.  Activated CD4+ T-cells from mice fed DHA display significantly increased surface expression of CD28.  A: Time 
course analyses of the expression of CD28 molecules were carried out in CD4+ T-cells cultured in the presence of 10% FBS from 
mice fed CO, DHA, or EPA.  The y-axis represents the antibody binding capacity (ABC) equivalent sites for CD28 after culture with 
phorbol ester (PMA) and calcium ionophore (Ionomycin).  Values represent means ±SEM of cultures from 6-10 mice. *Highly 
significant differences were found between DHA and CO-fed mice (p<0.01) Inset: Histogram represents the mean fluorescence of 
anti-CD28-PE. CO (dotted line), DHA (solid line), or EPA (dashed line)  B: CD28 mRNA quantification of CD4+ T-cells from mice 
fed CO, DHA, or EPA was performed by real-time RT-PCR.  Values for cycle threshold (Ct) were converted to “expression levels” to 
allow for fold comparisons between samples, expression level =2(40-Ct).  Data were normalized to 18S rRNA and expressed as means 
±SEM, n=6-10.  *Significant differences were found between control (CO) and experimental diet groups p<0.05.   
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surface expression (Fig. 3A and 3B).  This is consistent with previous reports 
demonstrating that anti-CD28 mAb augments anti-CD3-induced CTLA-4 surface 
expression (123, 124).  In vitro culture with PMA/Iono stimuli (used in Fig. 2) for CD28 
analysis failed to induce CTLA-4 expression (data not shown). 
Although the absolute values differed, the kinetics of both total and surface 
CTLA-4 protein expression were similar for all diet groups.  Consistent with other 
findings, mice fed the CO control diet displayed a continuous increase in CTLA-4 protein 
expression over time as antibody binding capacity (ABC) plateaued at 96 h post-
activation (Fig. 3A and 3B) (104).  However, CTLA-4 expression levels on CD4+ T-cells 
from mice fed the EPA diet reached significantly higher levels at 72 h of in vitro T-cell 
activation (p<0.01; Fig. 3A and 3B Inset).  It is noteworthy that CD4+ T-cells from mice 
fed dietary EPA had uniformly higher levels of CTLA-4 molecules than cells from mice 
fed CO, whereas cells from mice fed dietary DHA were heterogenous, with some time 
points behaving similarly to CO and others similar to the EPA-fed group.  These results 
demonstrate that dietary n-3 PUFA significantly and differentially enhance the temporal 
expression of both cell surface-expressed and total CTLA-4.   
Quantitative measurement of CTLA-4 mRNA expression showed enhanced 
transcript levels in mice fed dietary n-3 PUFA relative to CO (Fig. 3C).  Dietary DHA 
significantly enhanced CTLA-4 mRNA levels 72 h post-stimulation (p<0.05).  Unlike the 
CD28 analysis (Fig. 2), there was a direct relationship between CTLA-4 protein and 
transcript levels in CD4+ T-cells from mice fed dietary n-3 PUFA.   
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Anti-CTLA-4 mAb treatment in vivo and in vitro does not relieve the suppression of 
lymphocyte responses in mice fed dietary n-3 PUFA 
Since CTLA-4 has been implicated in down-modulating T-cell activation (89, 
106, 125, 126), and is significantly upregulated in CD4+ T-cells from mice fed dietary n-
3 PUFA, we next investigated whether CTLA-4 engagement was involved in diet-
mediated immunosuppression.  Splenic CD4+ T-cells from mice fed the experimental or 
control diets were cultured as described in Fig. 1 with the addition of anti-CTLA-4 (mAb 
clone UC10-4F10; BD Pharmingen) or IgG control.  As expected, dietary n-3 PUFA 
suppressed lymphocyte proliferation after in vitro activation (Fig. 4A).  The presence of 
CTLA-4 mAb in cultures had little effect on the T-cell proliferative responses of mice fed 
DHA and EPA (Fig. 4A).  When all diet groups were combined, the presence of CTLA-4 
mAb did, however, inhibit T-cell proliferation (Fig. 4B), although the difference was not 
statistically significant.  These results suggest that anti-CTLA-4 mAb does not enhance 
T-cell proliferation and may be suppressive when added to cultures suboptimally 
stimulated with anti-CD3 and anti-CD28 mAbs as previously observed by us (Fig. 5) and 
by Walunas et al (44).  Thus, in our  model, in vitro administration of mAb anti-CTLA-4 
appeared to deliver a positive signal through the CTLA-4 receptor to down-regulate T-
cell proliferation rather than block transduction of a negative signal. 
 To determine whether anti-CTLA-4 treatment in vivo could reverse the 
suppressive effect of diet, splenocytes from Mycobacterium bovis (BCG)-vaccinated 
mice were cultured for 96 h in the presence of HMS with purified protein derivative 
(PPD) or concanavalin A (ConA) to allow comparisons between antigenic and mitogenic 
stimulation.  Splenocytes taken from the CTLA-4 mAb treated group responded similarly  
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FIGURE 3.  Splenic CD4+ T-cells from mice fed dietary n-3 PUFA express significantly increased 
CTLA-4 protein (total and surface) and mRNA levels following in vitro activation.  Time course analyses 
of A: total and B: surface CTLA-4 expression were carried out in CD4+ T-cells from mice fed CO, DHA, 
or EPA in the presence of HMS.  The y-axis represents the antibody binding capacity (ABC) equivalent 
sites for CTLA-4 after culture with anti-CD3 and anti-CD28.  Values represent means ±SEM of cultures 
from n=6-7 mice.  *Highly significant differences were found between EPA and CO-fed mice (p<0.01).  
Inset: Histogram represents the mean fluorescence of anti-CTLA-4-PE.  CO (dotted line), DHA (solid line), 
or EPA (dashed line).  
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FIGURE 3.  Continued.  C: CTLA-4 mRNA quantification of CD4+ T-cells from mice fed CO, DHA, or 
EPA was performed by real-time RT-PCR as described in Fig. 2B.  *Significant differences were found 
between control (CO) and the experimental diet groups p<0.05. 
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FIGURE 4.  In vitro effect of CTLA-4 ligation with antibody on CD4+ T-cell proliferation.  A: Splenic CD4+ T-cells from mice fed 
diets enriched with CO, DHA, or EPA were stimulated with aCD3/aCD28 as described in Fig. 1B in the presence of either 100 mg/ml 
anti-CTLA-4 mAb (BD Pharmingen) or an isotype-matched control IgG (BD Pharmingen) (data not shown) in the presence of HMS.  
Cellular uptake of [3H]-thymidine was measured 72 h post-stimulation.  Results are expressed as the net disintegrations per minute 
(DPM), n=6.  Different letters denote highly significant differences between diet groups (p<0.01).  B: Bars represent all diet groups 
combined for each treatment in Fig. 4A.   
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FIGURE 5.  Anti-CTLA-4 antibody (Pharmingen) decreases CD4+T-cell proliferation in 
C57BL/6 mice.  Purified splenic CD4+ T-cells were obtained from C57BL/6 mice and cultured 
with αCD3/CD28 at 1 and 5 µg/ml, respectively, in the absence or presence of 100 µg/ml of anti-
mouse CTLA-4 Ab (clone 4F10; Pharmingen) or 100 µg/ml of IgG isotype (Iso; Pharmingen).  
Results are expressed as mean ± SEM of the net disintegrations per minute (DPM), n=3 mice. 
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as those obtained from the isotype control-treated group.  Anti-CTLA-4 mAb purified 
from UC10-4F10 hybridoma cells were tested for specificity (Fig. 6A) and activity (Fig. 
6B) prior to injections.  Dietary n-3 PUFA (DHA) significantly enhanced the 
proliferative response of splenocytes to mitogenic and antigenic stimuli from BCG-
vaccinated mice treated with either isotype or CTLA-4 mAb (Fig. 7A & 7B). 
 The effect of diet on the in vivo antigenic response was evaluated by footpad 
testing BCG-vaccinated mice treated with CTLA-4 mAb or isotype control with PPD 48 
h prior to sacrifice.  The difference in footpad thickness was measured with microcalipers 
before and 48 h after PPD injection.  Fig. 7C illustrates that both dietary n-3 PUFA 
significantly suppressed the delayed-type hypersensitivity (DTH) response to PPD in 
mice treated with the isotype control.  Surprisingly, treatment with the CTLA-4 mAb in 
the CO-fed group markedly reduced the DTH reaction (Fig. 7C), and further suppressed 
the response in the footpads of EPA-fed mice. 
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FIGURE 6.  Anti-CTLA-4 Ab (prepared in-house) enhances whole splenocyte proliferation in C57BL/6 
mice.  A: The specificity of the purified anti-CTLA-4 mAb from UC10-4F10 cells was determined by 
immunobloting.  The transfer blot of 0.25 µg of rmCTLA-4 Ab (R&D) was incubated with the purified 
anti-CTLA-4 Ab (no dilution) as the primary antibody.  The rmCTLA-4 protein migrates as a 55kDa 
protein.  B: Whole splenocytes were obtained from C57BL/6 mice and activated with anti-CD3 at 1 µg/ml 
or ConA 2.5 µg/ml in the presence or absence of 100µg/ml of anti-CTLA-4 Ab purchased from 
Pharmingen or prepared in-house from UC10-4F10 cells (refer to page 22) or 100µg/ml of IgG isotype Ab 
(Pharmingen).  Results are expressed as mean ± SEM of the net disintegrations per minute (DPM), n=3 
mice.  Letters denote highly significant differences found within the treatment group (p<0.01). 
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FIGURE 7.  Anti-CTLA-4 mAb treatment in vivo does not alter diet-induced changes in PPD-specific T-
cell responses of BCG-immunized mice.  Proliferative response of splenocytes from BCG-immunized mice 
to Concanavalin A (ConA; 2.5 µg/ml) and purified protein derivative (PPD; 10 µg/ml) in the presence of 
HMS after 96 h of culture.  Results are expressed as the mean ± SEM net thymidine uptake (DPM) of n=5-
6 mice per diet group.  Different letters denote highly significant differences found between diet groups 
(p<0.01). Mice were treated with, A: isotype control (IgG) or, B: anti-CTLA-4 at 100 µg/mouse daily for 5 
days prior to sacrifice.   
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FIGURE 7.  Continued.  C: DTH response to PPD in the footpads of BCG-immunized mice treated with 
isotype control or anti-CTLA-4 mAb as described above.  Results are expressed as the mean ± SEM of the 
difference in footpad thickness in millimeters (mm) as measured just before and 48 h after injection with 
PPD, n=5-6 mice per diet group.  Different letters denote highly significant differences found between 
treatment groups (p<0.01).  * Highly significant differences were found between CO vs. DHA and/or EPA-
fed mice within the treatment group (p<0.01). 
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Discussion 
Successful T-cell activation and clonal expansion, followed by appropriate  
homeostatic clonal contraction, require a delicate balance of positive and negative 
regulatory signals.  Costimulatory molecules such as CD28 are essential coactivators of 
proliferation, cytokine production, and cell migration (127-129).  To balance these 
signals, cell surface molecules like CTLA-4 inhibit T-cell responses.  We have shown 
here that dietary n-3 PUFA feeding alters CD28 and CTLA-4 co-receptor expression, 
apparently disrupting the balance between these two signals to favor reduced T-cell 
activation.   
New data have identified an important link between the co-receptors and the 
expression of lipid rafts on the surface of T-cells.  Lipid rafts segregate proteins and 
lipids into liquid-ordered domains with distinct biophysical properties (130).  Crucial 
signaling proteins reside in these domains and engagement of the TcR with antigen 
promotes the entry of receptors into rafts, in which the TcRs are likely to interact with 
kinases and adaptors (131, 132).  Viola et al (118) first showed that ligation of CD28 
promotes the cell-surface expression of lipid rafts, whereas Martin et al (133) showed that 
CTLA-4 potentially inhibits TcR-CD28-mediated raft formation.  In this model, 
costimulatory receptors would function by simply regulating the availability of crucial 
signal mediators that are required for effective TcR signaling.  We and others have 
previously reported that dietary n-3 PUFA differentially modulate the phospholipid 
membrane composition of lymphocytes, thereby attenuating T-cell function by altering 
the recruitment of critical components of the TcR signal transduction machinery (58, 61).  
Dietary n-3 PUFA feeding reduced the translocation of PKCθ into lipid rafts, and 
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inhibited both AP-1 and NF-κB activation, and IL-2 secretion (62).  On this background, 
we hypothesize that dietary n-3 PUFA will also alter the interaction of CD28 and/or 
CTLA-4 with lipid rafts to influence the development of the immunological synapse (IS) 
during T-cell-APC-conjugate formation (134).  This hypothesis will be the focus of 
subsequent studies.   
 Our results indicate that dietary n-3 PUFA feeding upregulated both CD28 and 
CTLA-4 protein expression levels (Fig. 2 and 3).  However, DHA and EPA, the active 
constituents of fish oil, exhibited somewhat different immunomodulatory properties.  
DHA significantly enhanced the cell surface expression of CD28 on CD4+ T-cells (Fig. 
2A; t= 48 h post-activation), while dietary EPA upregulated CTLA-4 protein (surface and 
total) (Fig. 3A and B; t=72 h post-activation).  Furthermore, our results indicate that 
CTLA-4 mRNA levels were significantly increased in only the DHA-fed group (Fig. 3C).  
Although both experimental diets suppressed CD4+ T-cell proliferation in a similar 
manner (Fig. 1), it is clear that EPA and DHA have unique effects on co-stimulatory 
regulation in our model.  Consistent with our findings, a recent human study (135) 
concluded that EPA and DHA differentially modulate certain immune functions.  In that 
study, the fatty acid composition of plasma phospholipids in neutrophils was 
differentially altered by supplementation with DHA or EPA.  Supplementation with DHA 
suppressed T-lymphocyte activation, as assessed by CD69 expression, whereas EPA 
supplementation had no significant effect.  The mechanisms responsible for the 
differential effects of EPA and DHA on T-lymphocyte activation are unclear.  EPA and 
DHA may conceivably have different effects on raft stability because DHA is thought to 
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adopt a more folded conformation in membranes and has been shown to exclude 
phospholipase D from lipid rafts at relatively low concentrations (136).   
 The molecular basis for T-cell inhibition by CTLA-4 has been the subject of 
much debate.  It has been proposed that CTLA-4 may: 1) antagonize CD28 by competing 
for CD80 or CD86 binding; 2) sequester intracellular enzymes that can bind to both co-
receptors; or 3) directly or indirectly reduce TcR signals by association with the 
immunological synapse (137).  The kinetics of CTLA-4 expression were dramatically 
modified by dietary n-3 PUFA feeding in our study such that the protein levels (surface 
and total) approached maximum levels 72 h post-activation in vitro (EPA >> DHA; Fig. 
3A and B).  The CO-fed group did not reach maximum CTLA-4 protein expression levels 
until after 96 h.  These results suggest that the down-regulatory CTLA-4 co-receptor may 
play a key role in diet-mediated immunosuppression (Fig. 1), i.e., dietary n-3 PUFA may 
rapidly upregulate CTLA-4 protein expression to downregulate overall T-cell function.   
 Although the cell surface levels of CD28 protein were also significantly enhanced 
by n-3 PUFA (DHA; Fig. 2) feeding, there was a dissociation with its mRNA expression 
(Fig. 2B).  In contrast, a direct relationship was observed between CTLA-4 transcript and 
protein levels (Fig. 3).  Since dietary n-3 PUFA increased the expression of CD28, which 
is inconsistent with suppressed T-cell proliferation, it is conceivable that the increased 
levels of CD28 on the cell surface may not be functional.  It is possible that by altering 
the fatty acid composition of the cellular membrane, diet may inhibit the positive 
regulatory function of CD28 on the T-cell response.  We and others have recently 
reported that conditions which modify raft structure can disrupt the earliest steps of T-cell 
activation and the function of those critical signaling components (56, 58, 61). 
   
 42
In vitro experiments have shown that the blockade of signals through CTLA-4 
augments T-cell expansion, while CTLA-4 cross-linking results in decreased T-cell 
proliferation due to decreased IL-2 production (138).  The experiments presented here 
suggest that the latter mechanism was operational in our cultures, as the presence of 
CTLA-4 mAb (4F10) in culture with CD4+ T-cells activated with αCD3/αCD28 certainly 
did not enhance, and may have reduced, cell proliferation, although the latter effect was 
not statistically significant (Fig. 4).   
 The effect of CTLA-4 blockade in vivo was first demonstrated in a tumor model 
in which an enhanced antitumor immunity was observed (139).  In other experimental 
systems, CTLA-4 blockade enhanced the severity of autoimmune diseases by increasing 
the pool of pathologic T-cells (115, 140).  Taken together, these findings indicate that 
antibody ligation of  CTLA-4 in some in vivo models leads to an enhanced T-cell 
response.  In contrast, we demonstrate that anti-CTLA-4 treatment in vivo may have had 
an agonist effect.  Both dietary n-3 PUFA significantly reduced the DTH response of 
BCG-immunized mice treated with the IgG isotype control, whereas in mice treated in 
vivo with anti-CTLA-4 mAb, no relief of this diet-mediated suppression was seen.  In 
fact, further suppression of DTH was observed in the EPA-fed group treated with 
antibody (Fig. 7C; p<0.01).  Anti-CTLA-4 mAb also markedly reduced the DTH 
response of mice fed the control diet (CO; p<0.01) suggesting that the in vivo mAb 
treatment may have had a positive, agonist effect on the lymphocytes.   
 As previously reported by our laboratory, the enhancing effect of EPA and DHA 
on mitogen-induced proliferation in the splenocytes of BCG-vaccinated mice may be 
explained, in part, by alteration in the proportions of functional T-cell subsets (e.g., Th1 
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& Th2) as well as the relative proportions of activated and/or memory T-cells populating 
the spleens of mice undergoing a vigorous immune response to an on-going BCG 
infection (3).  It has been reported that CTLA-4 protein expression is much higher in Th2 
than in Th1 clones (141).  Therefore, it may not be surprising that CTLA-4 ligation in 
vivo with mAb in BCG-vaccinated mice with a predominantly Th1 cell response did not 
affect the mitogen and antigen-induced proliferative response of splenocytes from mice 
fed dietary n-3 PUFA (Fig. 7A & 7B).  Moreover, the presence of CTLA-4 mAb in vitro 
did not significantly alter [H3]-thymidine uptake of αCD3/αCD28-stimulated CD4+ T-
cells from naïve mice fed dietary n-3 PUFA (Fig. 4).  The presence of anti-CTLA-4 mAb 
in vitro and in vivo did, however, have differential effects on lymphocyte proliferation in 
mice fed dietary n-3 PUFA (Fig. 4 & 7).  This may be explained, in part, by the presence 
of accessory cells in whole splenocyte cultures from mice treated in vivo with mAb (Fig. 
7) and the lack thereof in the purified CD4+ T-cell cultures (Fig. 4).  Although there is 
evidence that dietary n-3 PUFA affect accessory cell membrane lipid composition and 
cytokine production (142-145), we and others have shown that the diet-mediated T-cell 
immunosuppression is mediated principally through direct effects on T-cells (3, 4, 10, 
146). 
 The suppressive effect of dietary n-3 PUFA can also be attributed to a 
subpopulation of CD4+ T-cells known as regulatory T-cells (Tregs; CD4+ CD25+), which 
are immunosuppressive in vivo and in vitro (147, 148).  Thymic-derived Tregs have been 
shown to regulate autoimmune disease via active suppression of self-reactive T-cells in 
various models of autoimmunity (149).  It has recently been demonstrated that CD28 
maintains a stable pool of peripheral Tregs by both supporting their survival and 
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promoting their self-renewal (150).  CD28 engagement promotes survival by regulating 
IL-2 production by conventional T-cells and CD25 expression on Tregs.  Since CD28 
protein expression is upregulated on the surface of CD4+ T-cells (Fig. 2), from mice fed 
dietary n-3 PUFA, it would be of interest to determine whether the CD4+ CD25+ 
subpopulation play a role in mediating diet-induced T-cell suppression.  
Our data suggest that the enhanced CTLA-4 cell surface protein expressed on the 
CD4+ T-cells of mice fed EPA may not be functional, and that factors other than CTLA-4 
may be responsible for diet-mediated immunosuppression.  It seems likely that the 
complex interplay between functional CD28 and CTLA-4, and their association (or the 
lack thereof) with plasma membrane microdomains (“raft”) may be responsible, in part, 
for the downregulatory effect of diet on T-cell function in this model.  Characterization of 
the co-receptors in relation to lipid rafts following T-cell stimulation will allow a 
determination of the precise role that altered levels of CD28 and CTLA-4 play in the diet-
mediated regulation of T-cell function.   
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CHAPTER III 
DIETARY N-3 POLYUNSATURATED FATTY ACIDS 
SUPPRESS SPLENIC CD4+  T-CELL FUNCTION IN IL-10(-/-) MICE* 
Introduction 
 IL-10 is a major regulatory cytokine of inflammatory responses.  It was originally 
described as a mouse Th2 cell factor, inhibiting cytokine synthesis by Th1 cells (151).  
However, increasing evidence suggests that IL-10 acts as a general inhibitor of 
proliferative and cytokine responses of both Th1 and Th2 cells in vitro and in vivo (152-
154).  IL-10 is released by mononuclear phagocytes (152, 153), natural killer cells and by 
both Th1 and Th2 type lymphocytes (154).  Its production is tightly regulated, as excess 
IL-10 leads to the inability to control infectious pathogens, while insufficient IL-10 leads 
to the pathology secondary to tissue injury.  The immunosuppressive potency of IL-10 
depends on the timing of IL-10 and IL-10 receptor (IL-10R) expression, and the IL-10 
suppressive activity can diminish during immune and inflammatory responses (155, 156). 
 The co-stimulatory signal induced by complexing CD28 with specific monoclonal 
antibodies (mAbs) or by interaction with B7 counter-receptors enhances the antigen-
dependent T-cell proliferation and cytokine production (102, 157).  It has been proven 
that IL-10 elicits tolerance in T-cells by selective inhibition of the CD28 co-stimulatory 
pathway and thereby controls suppression and development of antigen specific immunity.  
IL-10 only inhibits T-cells stimulated by the engagement of low numbers of T-cell  
 
 
__________ 
*Reprinted with permission from “Dietary n-3 Polyunsaturated Fatty Acids Suppress 
Splenic CD4+  T-cell Function in IL-10(-/-) mice” by Ly, L.H., et al, 2004. Clinical and 
Experimental Immunology (accepted).  2004 by Blackwell Publishing. 
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receptors, i.e., conditions which require CD28 co-stimulation (66, 67).  IL-10 inhibited 
CD28 tyrosine phosphorylation, the initial step of the CD28 signaling pathway, and  
consequently the phosphatidylinositol 3-kinase p85 binding to CD28 (67).  In addition, 
Akdis et al demonstrated that stimulation of CD45RO+ memory T-cells from healthy 
human subjects up-regulated IL-10 receptor (IL-10R) expression, rendering the cells 
more susceptible to IL-10-mediated suppression.  The IL-10-induced selective inhibition 
of the CD28 co-stimulatory pathway acts as a decisive mechanism in determining 
whether a T-cell will contribute to an immune response or become anergic. 
  Previous results from our laboratory show that T-lymphocytes from mice fed the 
predominant n-3 polyunsaturated fatty acids (PUFA), docosahexaenoic acid (DHA; 22:6) 
and eicosapentaenoic acid (EPA; 20:5), found in fish oil (FO) produced significantly less 
IL-2, but only when cells were activated with αCD3/CD28 and not when activated with 
αCD3/PMA (phorbol ester) (4).  Furthermore, dietary n-3 PUFA significantly enhanced 
the expression of CD28 on the surface of CD4+ T-cells (Chapter II). 
 On this background, we hypothesized that the suppressive effects of diet would be 
mediated by IL-10 and its relationship with CD28.  To investigate this hypothesis, we 
have determined the influence of dietary DHA and EPA on the proliferative response, 
kinetics of IL-10R expression, and anti-inflammatory cytokine production of purified 
splenic CD4+ T-cells from conventional C57BL/6 and IL-10 gene knockout (IL-10-/-) 
mice.  Surprisingly, all responses were similar in both mouse groups with the exception 
of cytokine production.  Dietary n-3 PUFA significantly reduced IFNγ production in 
conventional mice while dramatically upregulating extracellular IFNγ in IL-10-/- mice.  
Therefore, we conclude that dietary n-3 PUFA suppress CD4+ T-cell functions through 
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mechanisms which do not involve IL-10.  Furthermore, our results suggest that dietary n-
3 PUFA may elicit the normally pro-inflammatory cytokine, IFNγ, to serve as an 
immunosuppressive cytokine in IL-10-deficient cells. 
 
Materials and Methods 
Diets and animals 
Female, pathogen-free, young (12-14g) C57BL/6 mice were purchased from the 
Frederick National Cancer Research Facility (Frederick, MD).  IL-10-/- mouse breeder 
pairs (129SvEv background) were a generous gift from Dr. Daniel Berg (University of 
Iowa).  The colony is maintained at the Laboratory Animal Resources and Research 
facility at Texas A&M University where all breeders were genotyped according to 
protocol (Jackson Laboratory, Bar Harbor, ME) (Fig. 8).  Female and male IL-10-/- (1-2 
months of age) and C57BL/6 mice were assigned to one of three semi-purified diets: 5% 
corn oil (CO) (control diet containing no n-3 PUFA), 1% DHA + 4% CO (DHA), or 1% 
EPA + 4% CO (EPA), for 14 days as described on page 17. 
 
Isolation and preparation of splenic lymphocytes  
Refer to page 18. 
 
CD4+ T-cell purification 
Refer to page 18. 
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T-cell proliferation 
Refer to page 19. 
 
T-cell activation for flow cytometry  
Refer to page 19. 
Immunofluorescence flow cytometry 
For quantitative surface receptor staining, 106 CD4+ T-cells from activated and 
control cultures were labeled with anti-IL-10R1 (PE, red) (BD Pharmingen) labeled mAb 
(4 µg/ml) and processed as described previously on page 20. 
 
ELISA analysis 
Activated CD4+ T-cells from C57BL/6 and IL-10-/- mice were analyzed for IFNγ 
and IL-10 production according to manufacturer’s protocol (R&D Systems). 
 
Statistical analysis 
Refer to page 23. 
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IGURE 8.  Representative gels of IL-10 knockout mouse genotyping.  The genetic makeup of 
the IL-10 knockout mouse (129 SvEv) colony breeders were confirmed by DNA isolation from 
 
                  1    2     3    4    5    6                  
 
Lane 1: molecular weight ladder 
Lane 2: C57BL/6 mouse (tail snip) 
Lane 3: IL-10 ko breeder (tail snip)                   
Lane 4: IL-10 ko breeder (DNA from blood) 
Lane 5: IL-10 ko breeder (DNA from blood)     
Lane 6: positive control from Dr. D. Berg
     
     
                        1   2   3   4   5   6   7   8 
       Lane 1: molecular weight ladder 
       Lane 2: IL-10ko breeder male cage #1 
          Lane 3: IL-10ko breeder female cage #1
       Lane 4: IL-10ko breeder male cage #2 
          Lane 5: IL-10ko breeder female cage #2
       Lane 6: IL-10ko breeder male cage #3 
       Lane 7: IL-10ko breeder female cage #3
       Lane 8: IL-10ko breeder male cage #4 
← 450 kDa
450 kDa →
200 kDa →
 
 
F
tail snips according to protocol from www.jax.org (see Appendix B).  Positive wild-type (+/+) 
and gene knockout (-/-) DNA migrates as a 200 kDa and 450 kDa protein, respectively. 
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Results  
-3 PUFA suppress CD4+ T-cell proliferation in C57BL/6 and IL-10(-/-) mice 
splenic
O; 
sed in 
ice 
 
 
ietary n-3 PUFA suppress IL-10 receptor (IL-10R) protein expression on the 
10R expression, kinetic 
 
significantly lower levels (>40%) of IL-10R molecules on a per-cell basis than those fed  
Dietary n
To determine the role of IL-10 in diet-mediated immunosuppression, purified 
 CD4+ T-cells from conventional C576BL/6 and IL-10(-/-) mice fed diets 
containing n-3 polyunsaturated fatty acids (PUFA), DHA or EPA, or corn oil (C
devoid of n-3 PUFA) for 14 d were activated with antibodies to CD3 and CD28 
(αCD3/CD28) for 72 h.  Surprisingly, cell proliferation was significantly suppres
both the C57BL/6 (Fig. 9A) and IL-10(-/-) mice (Fig. 9B) fed dietary n-3 PUFA.  Both 
dietary n-3 DHA and EPA significantly reduced T-cell proliferation in the C57BL/6 m
(Fig. 9A), whereas only EPA had a statistically significant effect on CD4+ T-cells from 
the IL-10(-/-) mice (Fig. 9B).  Therefore, absence of IL-10 does not alter the suppressive 
effect of dietary n-3 PUFA on polyclonal T-cell activation involving costimulation 
through CD28.  These results were contrary to our hypothesis that dietary n-3 PUFA
would not reduce CD4+ T-cell proliferation in IL-10(-/-) mice, thereby demonstrating a
role for the IL-10 cytokine in the suppressive effects of diet.  
 
D
surface of CD4+ T-cells from C57BL/6 and IL-10(-/-) mice 
 To elucidate the influence of dietary n-3 PUFA on IL-
analyses were performed on purified CD4+ T-cells from conventional and IL-10(-/-) mice 
fed the 3 diets.  As expected, activation of CD4+ T-cells with αCD3/CD28 upregulated 
cell surface expression of the IL-10R (Fig. 10).  Cells from C57BL/6 mice fed DHA had
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IGURE  9.  Dietary DHA and EPA down-regulate murine CD4  T-cell proliferation in IL-10-/- 
mice.  Purified splenic CD4+ T-cells from A: C57BL/6 and B: IL-10-/- mice fed CO, DHA, or 
PA were activated with antibodies to surface receptors CD3 and CD28 and cellular uptake of 
H]-thymidine was measured 72 h post-activation.  Results are expressed as mean ± SEM of the 
 
u  
F +
E
[3
net disintegrations per minute (DPM), n=5.  Different letters denote highly significant differences
found between diet groups (p<0.01).  All cells were cultured in the presence of 2.5% homologo s
mouse serum (HMS) + 2.5% FBS.  
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the CO (control) and EPA diet after 72 h of in vitro stimulation (p<0.01; Fig. 10A inset).  
Similarly, IL-10(-/-) mice fed dietary n-3 PUFA displayed markedly reduced levels of IL-
10R molecules 72 h post-activation (~35%; Fig. 10B inset).  In this instance, both dietary
DHA and EPA significantly suppressed the expression of the IL-10R.  These results 
indicate that dietary n-3 PUFA significantly and differentially reduce the temporal 
expression of cell surface-expressed IL-10R in both conventional and IL-10
 
. 
ietary n-3 PUFA differentially modulate IFNγ and IL-10 cytokine production in 
er investigate the mechanism by which dietary n-3 PUFA suppress CD4+ 
s recently 
 
e 
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y  
(-/-) mice
 
D
CD4+ T-cells  
 To furth
T-cell function in conventional and IL-10(-/-) mice, the production of the anti-  
inflammatory cytokine, IL-10, in cell culture supernatants was measured.  It ha
been reported that the pro-inflammatory IFNγ cytokine possesses anti-inflammatory 
properties and actively regulates IL-10 activity (158, 159).  Thus, it was of interest to
measure IFNγ production as a potential anti-inflammatory mediator.  Purified CD4+ T-
cells were stimulated with αCD3/CD28 for 48 h and cell supernatants were collected.  
Quantitative determination of IL-10 concentrations from C57BL/6 mice revealed that th
DHA-fed group produced significantly less (>50%) IL-10 than those fed the CO diet, 
whereas the EPA-fed group secreted dramatically more (2-fold) of the suppressive 
cytokine (Fig. 11A).  These results confirm that the anti-inflammatory cytokine IL-1
does not play a role in the suppression of CD4+ T-cell proliferation by DHA from 
C57BL/6 mice (Fig. 9A).  On the other hand, the immunosuppressive EPA diet ma
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utilize IL-10 by upregulating its expression.  ELISA analysis of IFNγ production in the 
same CD4+ T-cell culture supernatants showed that both DHA (p<0.01) and EPA 
(p=0.01) diets significantly reduced IFNγ production (Fig. 11B).  This strongly suggests 
that IFNγ does not mediate the suppressive effects of dietary n-3 PUFA on the T-cell 
response in C57BL/6 mice. 
 The production of IFNγ was also quantitated in cell supernatants from IL-10(-/-) 
mice.  Fig. 12 illustrates that dietary n-3 PUFA feeding significantly upregulated IFNγ 
production by CD4+ T-cells (>40%).  Overall, the levels of IFNγ in the supernatants of 
IL-10(-/-) CD4+ T-cells was 20-100 fold higher than those observed under identical culture 
conditions in CD4+ T-cells from conventional C57BL/6 mice (Fig. 11B).  Our results 
indicate that T-cells from IL-10(-/-) mice may utilize the anti-inflammatory properties of 
IFNγ to down-regulate T-cell function (Fig. 9B).  This may occur to compensate for the 
lack of available IL-10 within the cytokine network.   
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FIGURE 11.  Dietary n-3 PUFA differentially modulate CD4+ T-cell IFNγ and IL-10 production in 
C L/6 mice.  Purified splenic CD4+ T-cells from mice fed the 3 diets were activated with αCD3/CD28 
in the presence of 2.5% HMS + 2.5% FBS for 48 h.  A: IL-10 and B: IFNγ in culture supernatant fluids 
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FIGURE 12.  Dietary n-3 PUFA enhance IFNγ production in CD4+ T-cells from IL-10-/- mice.  Purified 
splenic CD4+ T-cells from mice fed the 3 diets were activated with αCD3/CD28 in the presence of 2.5% 
HMS + 2.5% FBS for 48 h.  IFNγ production in culture supernatant fluids was quantified by ELISA as 
described in the Materials and Methods.  Values from n=5 mice represent the mean ± SEM in pg/200,000 
cells.  Different letters denote highly significant differences found between diet groups (p<0.01). 
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FIGURE 13.  Diagram of results obtained from C57BL/6 mice.   
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FIGURE 14.  Diagram of results obtained from IL-10-/- mice. 
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Figures 13 and 14 diagram the results of this section obtained in C57BL/6 and IL-10-/- 
ice. 
 
Discussion
m
 
 The immunosuppressive role of IL-10 has been demonstrated by several human 
and mouse studies (160-163).  Inflammatory bowel disease and other exaggerated 
inflammatory responses exhibited by IL-10-/- mice indicated that a critical in vivo function 
of IL-10 is to limit inflammatory responses (164-166).  Moreover, inhibition of graft-
versus-host disease by IL-10 and allograft rejection in human leukocyte antigen-
mismatched bone-marrow transplantation in severe combined immunodeficient patients 
gives further evidence for a key role of this cytokine in the induction and maintenance of 
anergy (167).   
 The biological effects of cytokines are mediated through cell surface receptors.  
These receptors transduce the binding of their cytokines into cytoplasmic signals that 
eventually trigger a cascade of intracellular responses.  The functional receptor complex 
of IL-10 consists of at least 2 subunits IL-10R1 and IL-10R2, both of which have been 
characterized and shown to play critical roles in determining whether cells respond to IL-
0 (168-172).   
Our data in this current study strongly suggest that the anti-inflammatory effects 
f diets enriched in n-3 PUFA are not likely mediated by IL-10.  Fig. 9 and 10 illustrate 
ontinued to suppress CD4+ T-lymphocyte responses in the 
absence of endogenous IL-10.  Conventional C57BL/6 mice fed EPA may utilize the 
hibitory IL-10 cytokine to suppress T-cell function (Fig. 9A and 11A), although the IL-
1
 
o
that dietary n-3 PUFA c
in
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10R expression levels remained unaltered (Fig. 10A).  However, in similar mice fed the
DHA d
 
iet, alternative mechanisms may explain the suppressive effect of diet as both 
FNγ and IL-10 cytokine production were down-regulated (Fig. 11).   
de the inhibitory effect of IL-10, other mechanisms acting on co-stimulatory 
  
eic 
P-
the TCR 
cells (Chapter II), thereby disrupting the balance between these two 
 
ory properties.  In this study, both EPA and DHA significantly reduced 
D4+ T
ement 
y 
I
 Besi
pathways have been demonstrated to render T-cells unresponsive to an antigenic trigger.
Blocking of the CD28-B7 interaction by CTLA-4 leads to an inhibition of xenogen
graft rejection of pancreatic islets in mice (173).  It has been shown that CTLA-4 forms a 
multimolecular complex with TCRξ and an SH2-containing tyrosine phosphatase (SH
2), leading to a direct dephosphorylation of TCRξ and a subsequent inhibition of 
signaling pathway (174).  We recently demonstrated that dietary n-3 PUFA feeding 
significantly upregulated both CD28 and CTLA-4 protein expression on the surface of 
murine CD4+ T-
signals to favor reduced T-cell activation.  These findings are relevant to elucidate the 
mechanism(s) by which diet reduces T-cell function, without the involvement of IL-10
(Fig. 6 and 7), in conventional mice.  Further studies will be needed to determine the 
extent to which CTLA-4 plays a role in diet-mediated immunosuppression.   
 Not surprisingly, dietary DHA and EPA exhibited somewhat different 
immunomodulat
C -cell proliferation in C57BL/6 mice.  EPA also suppressed this response 
significantly in IL-10-/- mice (Fig. 9).  While proliferation was suppressed to nearly the 
same level by dietary DHA, the difference was not statistically significant.  Measur
of IL-10R expression levels revealed that conventional mice fed DHA had significantl
lower levels than the CO-fed group, while both DHA and EPA significantly reduced IL-
   
 61
10R cell surface molecules in IL-10(-/-) mice (Fig. 10; t=72 h post-activation).  
Furthermore, our results indicate that the EPA diet reduced IFNγ but enhanced IL-10 
production, while the DHA diet down-regulated both cytokines in C57BL/6 mice (Fig. 
are 
 and 
l 
nd adaptive 
ch as 
e 
 
11).  Although both experimental diets up-regulated production of IFNγ in IL-10(-/-) mice 
in a similar manner (Fig. 12), it is clear that EPA and DHA have unique effects on certain 
T-lymphocyte responses in our model.  Consistent with these current findings, we 
recently reported that dietary DHA and EPA differentially altered co-stimulatory 
regulation as DHA significantly enhanced the cell surface expression of CD28, while 
dietary EPA up-regulated the expression of CTLA-4 (Chapter II).  The mechanisms 
responsible for the differential effects of EPA and DHA on T-lymphoctye responses 
unclear.  EPA and DHA may conceivably have different effects on membrane raft 
stability because DHA is thought to adopt a more folded conformation in membranes
has been shown to exclude phospholipase D from lipid rafts (136).  We have recently 
demonstrated an effect of dietary n-3 PUFA on T-cell lipid raft composition in our mode
(56). 
Production of IFNγ in response to infection is the hallmark of innate a
immunity (175).  IFNγ up-regulates a variety of pro-inflammatory mediators su
interleukin (IL)-12, IL-15, TNF-α, iNOS, and caspase-1 (176-179).  IL-10 and IFNγ hav
opposing effects during an active phase of an immune or inflammatory response,
characterized by high levels of IFNγ production and modest IL-10 activity such that 
pathogens can be effectively cleared (155, 180).  These pro-inflammatory characteristics 
of IFNγ contradict certain aspects of its biologic activity.  Treatment of rheumatoid 
arthritis with IFNγ in mouse and human studies was associated with a reduction of 
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leukocyte influx into the synovium, less synovial hyperplasia and erosion, and 
clinical status (181, 182).  Similarly, administration of IFNγ markedly reduced the 
incidence of disease in a rat model of insulin-dependent diabetes mellitus (183). In 
contrast, IFNγ has been implicated in the pathophysiology of multiple sclerosis (MS) 
patients (184).  The mechanisms by which the pro-inflammatory IFNγ may exert anti-
inflammatory properties has recently been reviewed (158).  The authors conclude t
IFNγ re-directs inflammatory responses by inhibiting production of pro-inflammat
1 and IL-8, by up-regulating the production of cytokine antagonists such as IL-1Ra and
IL-18BP, inducing expression of the suppressors of cytokine signaling (SOCS), and b
inducing apoptosis in leukocytes and local resident cells.  The biological triggers 
responsible for shifting the role of IFNγ from pro- to anti-inflammatory in response
immunologic stimuli have not been elucidated.  However, these anti-inflammatory 
properties of the principally pro-inflammatory cytokine may explain, in part, its enhan
production in suppressed T-cells from IL-10
improved 
hat 
ory IL-
 
y 
 to 
ced 
 clear indication of this compensatory role for IFNγ is the overall increase in IFNγ 
produc
(65).  
nses 
-/- mice fed dietary n-3 PUFA (Fig. 9B and 
12).  A
tion in lymphocytes from IL-10-/- vs. C57BL/6 mice (20-100-fold; Fig. 11B and 
12).  Further experiments will be necessary to examine the anti-inflammatory role of 
IFNγ in IL-10-/- mice fed dietary n-3 PUFA. 
 The dual role of IFNγ is also mimicked by the pleiotropic effects of IL-10 
Administration of IL-10 to wild-type mice can inhibit antigen-specific immune respo
in vivo (185).  In mice and humans, IL-10 can induce long-term antigen-specific anergy 
in CD4+ T-cells (64, 186).  In humans, IL-10 has a role in inducing systemic lupus 
erythematosus (187), yet counteracts psoriasis (188), and Crohn’s disease (189).  
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Intravenous administration of IL-10 to healthy donors has proinflammatory effects 
through the release of IFNγ, IFNγ-inducible protein (IP-10) and increased granzyme
levels (190).  These effects are counteracted by inhibition of the release of monocyt
inflammatory protein-1α (MIP-1α), MIP-1β and monocyte chemotactic protein-1 (MC
1) (191), TNF-α, IL-1β and IL-6 (155), and T-cell function (192).  A switch in cytokin
activity that is induced by the absence of an opposing cytokine adds an additional level
complexity to cytokine cross-regulation and cooperation pathways, especially when an 
immunosuppressive diet is involved.   
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 The 20- and 22-carbon n-3 PUFA are unique lipids in that they possess potent 
immunomodulatory activities.  In addition, dietary n-3 PUFA have effects on diverse 
physiological processes impacting normal health and chronic disease, such as the 
regulation of plasma lipid levels (193-196), cardiovascular function (197-199), insulin 
action (200, 201), and neuronal development and visual function (202).  Ingestion of n-3
PUFA results in their distribution to vir
 
tually every cell in the body affecting membrane 
composition and function, signaling, and regulation of gene expression (202-204).  
However, cell-specific lipid metabolism as well as the expression of fatty acid-regulated 
anscription factors will likely play a role in determining how the cell responds to 
hanges in n-3 PUFA composition.   
There is strong evidence for the beneficial effects of dietary FO in patients with 
hronic rheumatoid arthritis (205-208).  Animal studies, including ours, indicate that diets 
ch in EPA and DHA are anti-inflammatory and immunomodulatory in vivo.  However, 
e specific mechanisms by which these effects occur remain unclear.  The literature is 
plete with inconsistencies because many laboratories use different amounts or types of 
t in the administered diet, employ different strains of mice, and measure lymphocyte 
sponses using various cell populations and stimuli (reviewed by (209)).  In our studies, 
 is clear that the suppressive effects of n-3 PUFA on T-cell function can, in part, be 
ttributed to alterations in co-stimulatory receptor function and cytokine cross-talk.  
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Our results suggest that dieta upts the regulatory interplay 
between T-cell membrane compensate for the lack 
ed 
he 
 co-
ith CTLA-4 mAb in vivo in Mycobacterium bovis 
 
e 
 
immunosuppression, studies involving CD28 and CTLA-4 gene knockout mice (lacking a 
costimulatory signal for T-cell activation or deactivation) would be very helpful.  It is 
ry n-3 PUFA disr
 co-receptors, CD28 and CTLA-4.  To 
of functional endogenous IL-10, the anti-inflammatory aspects of IFNγ may be enhanc
in IL-10-/- mice fed dietary n-3 PUFA.  These data give us a glimpse into the possible 
mechanisms by which dietary n-3 PUFA exert their immunosuppressive effects.  T
most important conclusions of this study are summarized here: 
• Dietary n-3 PUFA (DHA>EPA) significantly reduced the in vitro 
proliferation of purified CD4+ T-cell in mice. 
• The suppressive effects of dietary n-3 PUFA were amplified by the 
presence of homologous mouse serum (HMS) in vitro. 
• The suppressive effects of diet do not appear to involve the CTLA-4
receptor, as treatment w
(BCG)-vaccinated mice did not alter the suppressive effects of dietary n-3
PUFA on antigen (PPD)-induced lymphocyte proliferation or delayed 
hypersensitivity reactions. 
• The downregulatory effects of dietary n-3 PUFA did not appear to involv
the suppressive IL-10 cytokine, as the proliferation of purified splenic 
CD4+ T-cells in n-3 PUFA fed IL-10-/- mice remained suppressed. 
• In the absence of IL-10, IFNγ may serve as an anti-inflammatory cytokine,
T-cell suppressive role in IL-10-/- mice fed dietary n-3 PUFA. 
 To confirm the role of co-stimulatory molecules in n-3 PUFA diet-mediated 
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41).  Because surface 
molecules  Th2 
cells (212, 213  differential effects of 
dietary n-3
 IL-10 p s the ability to 
control som in y 
to immune-me  
and activates r
kinases, leadin
transcription (S quired for the many anti-inflammatory effects 
of IL-10 (6  
One ke rs 
of cytokine sig ultiple 
cytokines, l
215).  Thus, SO m among 
as 
ld 
d that in the absence of these co-receptors, the suppressive effects of n-3 PU
feeding would diminish.  Since CD28 is known to play a pivotal role (129, 210, 211) in 
the induction of Th2 cytokines, it would be of interest to examine the levels of a 
prototypic Th2 cytokine (IL-4 or IL-10) in CD28 knockout mice.  Although the role of
CTLA-4 in Th1 and Th2 cells is debatable (113), recent studies have demonstrated tha
Th2 clones express higher levels of CTLA-4 than Th1 clones (1
and raft composition have been shown to behave differently in Th1 and
), further studies will be needed to delineate the
 PUFA on both CD4+ T-cell subsets. 
roduction is tightly regulated, as excessive IL-10 impair
e fectious pathogens, while insufficient IL-10 leads to pathology secondar
diated tissue injury.  Like many other cytokines, IL-10 binds to its receptor
eceptor-associated Janus kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2) 
g to the phosphorylation of signal transducers and activators of 
TAT) proteins which are re
4).   
y mechanism that inhibits Jak-STAT signaling is induction of suppresso
naling (SOCS) proteins.  SOCS are rapidly induced in response to m
inc uding cytokines that activate the Jak-STAT pathway themselves (214, 
CS proteins play an important role in cross-talk and antagonis
different cytokines.  Recently, it was reported that IL-10 signaling on lymphocytes w
suppressed by IFNγ-induced SOCS1 (159).  Since dietary n-3 PUFA feeding suppressed 
CD4+ T-cell proliferation in IL-10-/- mice and enhanced the production of IFNγ, it wou
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be of interest to investigate the role of SOCS-induced switching of the normally pro-
inflammatory IFNγ to become anti-inflammatory.  These issues are complex and more 
research will be needed to understand and to elucidate the precise molecular mech
by which dietary n-3 PUFA modulate T-cell functions. 
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FIGU
57BL/6 mice. 
 
bjective:
RE A-1.  Dietary fish oil enhances proliferation of whole Peyer’s Patches in 
C
O  To determine the effect of 4% dietary fish oil (FO) + 1% corn oil (CO) vs. 5% 
O on the proliferation of whole Peyer’s Patches (PP) in C57BL/6 mice. 
ethodology:
C
 
M   Peyer’s patches were excised from the small intestines and placed in a 
etri dish containing complete tissue culture (TC) medium (10% heat-inactivated FBS 
rvine Scientific), 1% L-glutamine (Gibco), 1% Penicillin-Streptamycin (Gibco), 10 µM 
-mercaptoethanol (Sigma), and 50 µg/ml gentamicin sulfate (Gibco)).  The PP were 
en teased apart using 2 curved end forceps ver a wire filter (Fisher) and transferred to 
esh complete TC medium with gentamicin.  A syringe barrel was used to push 
mainder of matter through the mesh.  Using a pasteur pipet, the suspension was passed 
ver the wire filter once again before washing once by centrifugation at 200 x g  for 5 
inutes at RT.  Cells were resuspended in 1 ml complete TC medium containing 
entamicin and were passed through a sterile Nylon wool fiber (scrubbed and combed 
om Polysciences) column (~1 inch of cotton wool was packed loosely into the end of a 
asteur pipet) to remove adherent cells.  The column was then rinsed with 5 ml of the 
omplete TC medium containing gentamicin.  Viable cell numbers were determined by 
ypan blue exclusion and counting on a hemocytometer.  Cells were cultured as 
escribed on page 19.  Results are expressed as mean ± SEM of the net disintegrations 
er minute (DPM), n=2-3.  Different letters denote highly significant differences found 
etween diet groups (p<0.01).  All cells were cultured in the presence of 10% FBS. 
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IGURE A-2.  Dietary fish oil enhances interleukin-2 (IL-2) production oF
from C57BL/6 mice. 
 
Objective: To determine the effect of 4% dietary fish oil (FO) + 1% corn oil (CO) vs. 5% 
CO on the IL-2 production of CD3+ T-cells from C57BL/6 mice. 
 
Methodology: Mouse CD3+ T-cells were purified, cultured, and analyzed by ELISA for 
IL-2 production as described previously (4).  Values from n=5 mice represent the mean ± 
SEM in pg/200,000 cells.  Different letters denote highly significant differences found 
between diet groups (p<0.01).  All cells were cultured in the presence of 10% FBS. 
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IGURE A-3.  Analysis of the protein expression of PLCγ-1 in activated CD3+ T-cells 
bjective:
F
from chow-fed mice. 
 
O  To validate the assay procedures to be used to determine the influence of 
dietary n-3 PUFA on the protein expression of PLCγ-1. 
 
Methodology: 30 x 106 purified CD3+ T-cells from 3-4 chow-fed C57BL/6 mice were 
activated with αCD3/CD28 for the specified time (0-10 min).  Cells were then gently 
sed and analyzed for protein content.  200 µg of cell lysate protein was incubated with 
0 µl of anti-phosphotyrosine (4G10) agarose conjugate overnight at 4°C.  Samples were 
luted using spin filters (Cytosignal) according to the manufacturer’s protocol and 
nalyzed by western blots using anti-mouse PLCγ-1 antibodies (1:1000; Upstate).  
esults are expressed as mean ± SEM of the relative band intensity after normalizing to 
0 min, n=3 pooled cultures. 
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FIGURE A-4.  Analysis of the protein expression of Zap-70 in activated CD3+ T-cells 
from chow-fed mice. 
 
Objective: To validate the assay procedures to be used to determine the influence of 
dietary n-3 PUFA on the protein expression of Zap-70. 
 
Methodology: 30 x 106 purified CD3+ T-cells from 3-4 chow-fed C57BL/6 mice were 
activated with αCD3/CD28 for the specified time (0-10 min).  Cells were then gently 
lysed and analyzed for protein content.  200 µg of cell lysate protein was incubated with 
20 µl of anti-phosphotyrosine (4G10) agarose conjugate overnight at 4°C.  Samples were 
eluted using spin filters (Cytosignal) according to the manufacturer’s protocol and 
analyzed by western blots using anti-mouse Zap-70 antibodies (1:1000; Upstate).  R
are expressed as mean ± SEM of the relative band intensity after normalizing to t=0 min,
n=3 pooled cultures. 
esults 
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FIGURE A-5.  Dietary fish oil (FO) does not alter protein expression of Zap-70 or PLCγ-1 in activated murine CD3+ 
T-cells.  
 
Objective: To determine the influence of 4% dietary FO on the protein expression of phosporylated Zap-70 and PLCγ-1 
in activated CD3+ T-cells from C57BL/6 mice.   
 
Methodology: : 30 x 106 purified CD3+ T-cells from 3-4 C57BL/6 mice fed the 5% corn oil (CO) or 4%  FO + 1% CO 
iets were activated with αCd
p
D3/CD28 for the specified time (min).  Cells were then gently lysed and analyzed for 
rotein content.  200 µg of cell lysate protein was incubated with 20 µl of anti-phosphotyrosine (4G10) agarose 
onjugate overnight at 4°C.  Samples were eluted using spin filters (Cytosignal) according to the manufacturer’s 
rotocol and analyzed by western blots using anti-mouse PLCγ-1 or anti-mouse Zap-70 antibodies (1:1000; Upstate).  
esults are expressed as mean ± SEM of the relative band intensity after normalizing to t=0 min, n=5 pooled cultures. 
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FIGURE A-6.  Th1-polarized CD4+ T-cells upregulate IFNγ production.  
 
Objective: To validate the Th1 polarization protocol on purified CD4+ T-cells from 
C57BL/6 mice. 
 
ethodology:
IFNγ IL-4
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Real-time PCR analysis
M  Splenic CD4+ T-cells from C57BL/6 mice were activated as previously 
escribed (58).  Values from n=5 mice represent the mean ± SEM in pg/200,000 cells. 
 using probes and primers designed for T-bet and GATA-3 mouse genes.   
d
T-cell RNA was obtained from similar cultures at day 5 post-activation as described on 
age 21p
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FIGURE A-7.  Dietary fish oil (FO) does not suppress whole splenocyte prolferation in 
-10(-/-) mice. IL
 
Objective: To determine the effect of dietary FO on whole splenocyte proli
(-/-)
feration in IL-
0  mice. 1
 
Methodology: W (-/-)hole splenocytes were obtained from IL-10  (129 SvEv) or 129 SvEv 
ontrol) mice fed the 5% corn oil (CO) or  4% FO + 1% CO diets for 5 or 10 weeks from 
d 
s 
 
(c
their date of arrival.  Cells were cultured as described on page 19.  Results are expresse
as mean ± SEM of the net disintegrations per minute (DPM), n=7 mice.  Different letter
denote highly significant differences found between diet groups (p<0.01).  All cells were
cultured in the presence of 10% FBS. 
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IGURE A-8.  Dietary fish oil (FO) reduces whole Peyer’s patches proliferation in IL-
0(-/-) mice. 
F
1
 
Objective: To determine the effect of dietary FO on whole Peyer’s patch proliferation in 
L-10(-/-)I  mice. 
 
Methodology: Whole Peyer’s patches were obtained (see A-1) from IL-10(-/-) (129 SvEv) 
r 9 SvEvo 12  (control) mice fed the 5% CO or 4% FO + 1% CO diets for 5 or 10 weeks 
 
 
from their date of arrival.  Cells were cultured as described on page 19.  Results are 
expressed as mean ± SEM of the net disintegrations per minute (DPM), n=2-3 pooled 
cultures.  Different letters denote highly significant differences found between diet 
groups (p<0.01).  All cells were cultured in the presence of 10% FBS. 
 
 
 
 
 
 
 
 
   
 106
 
 
 
 
 
9.  The presence of exogenous rIL-10 does not alter CD4+ T-cell 
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FIGURE A-
proliferation in C57BL/6 mice fed dietary n-3 PUFA. 
 
Objective: To determine if the presence of rIL-10 will enhance the suppressive effect of 
diet. 
 
Methodology: Splenic CD4+ T-cells from C57BL/6 mice fed dietary n-3 PUFA (1% ethyl 
ster + 4% corn oil (CO)) were cultured with αCD3 antibody at 0.5 µg/ml (CD3 low) or 
 µg/ml (CD3 high) in the presence or absence of 50 ng/ml of mouse rIL-10 (R&D 
ystems) for 72 h.  Results are expressed as mean ± SEM of the net disintegrations per 
inute (DPM), n=7 mice.  Different letters denote highly significant differences found 
etween diet groups (p<0.01).  All cells were cultured in the presence of 10% FBS. 
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FIGURE A-10.  Exogenous rIL-10 enhances CD4+ T-cell proliferation in IL-10(-/-) mice. 
 
 
 
Objective:  To determine the concentration at which recombinant mouse IL-10 (rIL-10) 
suppresses CD4+ T-cell proliferation in IL-10(-/-) mice. 
 
Methodology: Purified splenic CD4+ T-cells from IL-10(-/-) mice were stimulated with 
αCD3/CD28 (1 and 5 µg/ml, respectively) or ConA (2.5 µg/ml) with the specified 
concentrations of r IL-10 (ng/ml; R&D systems) for 72 h.  Results are expressed as mean 
 SEM of the net disintegrations per minute (DPM), n=4 mice.  Letters denote highly 
gnificant differences found within the treatment group (p<0.01). 
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IGURE A-11.  Exogenous rIL-10 enhances proliferative responses of whole Peyer’s 
atches in IL-10(-/-) mice. 
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Objective: To determine the concentration at which recombinant mouse IL-10 (rIL-10) 
(-/-)suppresses whole Peyer’s patches proliferation in IL-10  mice. 
 
Methodology: Whole Peyer’s patches were obtained (se (-/-)e A-1) from IL-10  mice and 
timulated with αCD3/CD28 (1 and 5 µg/ml, respectively) or ConA (2.5 µg/ml) with the 
d 
s
specified concentrations of r IL-10 (ng/ml; R&D systems) for 72 h.  Results are 
expressed as mean ± SEM of the net disintegrations per minute (DPM), n=2-3 poole
cultures.  Letters denote significant differences found within the treatment group 
(p<0.05). 
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FIGURE A-12.  Exogenous rIL-10 enhances cell proliferation in whole splenocyte and Peyer’s patches isolated from
IL-10(-/-) mice fed dietary n-3 PUFA. 
 
Objective: To determine if the dietary effect of n-3 PUFA on the proliferative responses of whole splenocyt
Peyer’s patches from IL-10
e and 
(-/-) mice can be reversed with the addition of rIL-10. 
 
Methodology: Whole splenocytes and Peyer’s patches (see A-1) from IL-10(-/-) mice fed dietary n-3 PUFA (1
ester + 4% co
spectively) or 
% ethyl 
rn oil (CO) or 4% fish oil (FO) + 1% CO) for 14 days were stimulated with αCD3/CD28 (1 and 5 µg/ml, 
ConA (2.5 µg/ml) in the presence or absence of 100 ng/ml rIL-10 (R&D systems) for 72 h.  Results are 
pressed as mean ± SEM of the net disintegrations per minute (DPM), n=6-13 mice.  Letters denote highly significant 
fferences found within the diet groups (p<0.01).  All cells were cultured in the presence of 10% FBS. 
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FIGURE A-13.  Anti-CTLA-4 Ab (Pharmingen) does not alter CD4+ T-cell prolifer
in C57BL/6 mice fed dietary n-3 PUFA. 
Objective: To determine the effect of anti-CTLA-4 (Ab) on CD4+ T-cell proliferation in 
C57BL/6 mice fed dietary n-3 PUFA.   
Methodology:
 
 Purified splenic CD4+ T-cells were obtained from C57BL/6 mice fed 
dietary n-3 PUFA (1% ethyl ester + 4% corn oil (CO)) for 14 days and cultured with 
αCD3/CD28 at 1 and 5 µg/ml, respectively, in the absence or presence of 100 µg/ml of 
nti-mouse CTLA-4 Ab (clone 4F10; Pharmingen) or 100 µg/ml of IgG isotype (Iso; 
harmingen).  Results are expressed as mean ± SEM of the net disintegrations per minute 
 (p<0.01).  All cells were cultured in the presence of 2.5% 
BS + 2.5% homologous mouse serum (HMS). 
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FIGURE A-14.  Dietary n-3 PUFA enhance whole splenocyte proliferation in both C57BL/6 and IL-10(-/-) mice. 
 
Objective: To determine the effect of dietary n-3 PUFA on the pr
57BL/6 and IL-10(-/-)
oliferative responses of whole splenocytes from 
ethodology:
C  mice. 
 
M  Whole splenocytes were obtained from C57BL/6 and IL-10(-/-) mice fed dietary n-3 PUFA for 14 days.  
ells were activated with αCD3/CD28 at 1 and 5µg/ml, respectively, for 72 h in the presence of 2.5% FBS + 2.5% 
omologous mouse serum (HMS).  Results are expressed as mean ± SEM of the net disintegrations per minute (DPM), 
=7 mice.  Letters denote highly significant differences found within the between diet groups (p<0.01).   
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FIGURE A-15.  Exogenous rIL-10 enhances whole splenocyte proliferation in IL-10
mice fed dietary n-3 PUFA. 
Objective: To determine the effect of recombinant mouse IL-10 (rIL-10) on whole 
splenocyte proliferation in IL-10(-/-) mice fed dietary n-3 PUFA. 
Methodology:
 
 Whole splenocytes were obtained from IL-10(-/-) mice fed dietary n-3 
PUFA for 14 days.  Cells were activated with αCD3/CD28 at 1 and 5µg/ml
for 72 h in the presence of 10% FBS.  Results are expressed as mean ± SEM of the net 
, respectively, 
inute (DPM), n=7 mice.  Letters denote highly significant 
ifferences found within the between diet groups (p<0.01).   
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APPENDIX B 
PROTOCOLS 
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Isolating Peyer’s Patches 
(from McGee, et al Immunology 1998 (64): 697-702 and Chapkin Lab) 
 
Materials: 
__forceps and scissors 
__PBS 
_small weigh boats (to collect and rinse intestines) 
_Complete PP media 
10% heat-inactivated FBS (Irvine Scientific), 1% L-glutamine (Gibco), 1% Penicillin-
Streptamycin (Gibco), 10 µM β-mercaptoethanol (Sigma), and 50 µg/ml gentamicin sulfate 
(Gibco)). 
_5 cc syringe 
_20 G needle 
_glass homogenizer 
_wire filter 
_nylon wool fiber column 
ack ~1 inch of cotton wool (scrubbed and combed from Polysciences, removes adherent cells) 
osely into the end of a pasteur pipet.  Sterilize 
_   1. Excise Peyer’s Patches (PP) (small, white nodules) from small intestines 
⇒ it may help to split open the small intestine and rinse out the feces in PBS to expose 
the PP.  However, most of the time the PP are noticeable without having to do this 
_   2. Transfer PP to a 15 ml. conical tube containing 5 ml. complete PP media 
_   3. Pipette PP solution into a glass-in-glass homogenizer and homogenize until completely 
broken up (~5-7 strokes) 
_   4. Assemble a 5 cc syringe, wire filter, and 20 gauge needle-unit for each PP and place on top 
of a newly labeled 15 ml. conical tube  
_   5. Remove the syringe plungers and transfer the PP suspension into the assembled unit 
_   6. Slowly reinsert the plunger to filter the suspension into the conical tube  
          ⇒ cells are fragile, so be gentle with this step 
__   7. Set up the nylon wool fiber column by placing a clothespin around the center of the 
column and ace it on an R&D T-cell column rack (the clothespin will help the column to 
stabilize on the rack) 
__   8. Place a new 15 ml. conical tube directly underneath the column to collect the eluent 
__   9. Pipette the PP solution at the top of the column and allow to flow through 
 ⇒ a bub ay develop at the top and may interfere with the flow.  Keep another aterile 
pasteur p  handy to eliminate any bubbles 
__   10. Wash the column with 5ml. complete PP media 
__   11. Spin cells own at 300 x g for 5 min. at RT 
__   12. Aspirate t pernatant and resuspend in 1ml. complete PP media 
__   13. Count cells on hemacytometer and adjust concentration if necessary 
_
_
 
_
_
_
_
_
P
lo
 
 
 
_
 
_
_
_
_
_
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 d
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Purifying CTLA-4 Antibody from UC10-4F10 cells 
04)) 
 
lls (as per protocol from ATCC)
(Lan Ly from Chapkin Lab (May 20
 
 
Growing UC10-4F10 ce  
  
BS, 11ml L-Glut, 5.5ml Na-Pyruvate, and 1.9µl 2-mercaptoethanol 
and pre-warm to 37C before use 
ecialty Media; S-002-D) 
edium (that has been warmed to 37C).    
_ 3. Spin at 300 x g for 5 min at RT 
_ 4. Aspirate supernatant and resuspend cells gently in 30 ml culture medium 
 at ~7-8) 
per 
n 
__ 8. R lture medium and count on hemacytometer 
__ 10. ribed above and aspirate or collect supernatant 
ic vials.   
 
Purify r manufacturer’s protocols)
 
Materials: 
 
__ UC10-4F10 cells from ATCC (HB-304) 
__ Culture medium: 
    Dulbecco’s modified Eagle’s medium (high glucose) (550ml) 
      -add 55ml F
      -store at 4C 
__ Freezing media (Sp
 
 
__ 1. Thaw frozen cells gently by rapid agitation in 37C water bath 
__ 2. Add contents of ampule to ~10 ml culture m
_
_
__ 5. Plate cells in T-75 flask for 2-3 days (medium will turn yellowish, but pH will remain
 ⇒  although this is a non-adherent cell line, ~50% of the cells will adhere to the flask as 
manufacturer 
__ 6. After 2-3 days, place contents of flask into 50 ml conical tube and spin dow
__ 7. Collect supernatant and freeze at –80C 
esuspend cells in 30 ml cu
__ 9. Maintain cultures at cell concentrations between 105 to 106 viable cells/ml 
 To freeze down cells, pellet cells as desc
__ 11. Resuspend the cells in culture freezing medium at a concentration of 107 to 108 as per 
manufacturer’s protocol 
__ 12. Freeze 1 ml of cells/ vial in appropriate cryogen
__ 13. Freeze gently and slowly to –80C using cryofreeze container 
ing Supernatants (as pe  
__ ake
    dd 
     -Add  L H20 
 
Materials: 
 
__ HiTrap Protein G HP affinity columns, 5 ml (Amersham, 17-0405-01) 
 M   20mM NaHPO4 solution (pH 7): 
 -A 1.38 g NaHPO4 (monobasic, pH 4.2, S-369) to 0.5 L H20 
 2.68 g NaHPO4 (dibasic, pH 9.2, S-373) to 0.5
     -Combine above solutions in 1L bottle and pH to ~7.0
     -Store at RT 
__ 5 ml syringe (luer-lok) 
__ Make 0.1 M Glycine solution (pH 2.7): 
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- Add 3.75 g Glycine to H20 
- Adjust pH to ~2.7 and bring up to 0.5 L 
- Store at RT 
__ Make 1 M T
 - Add 15.76 g Tris to H2
- Adjust pH to ~9.0 and bring up to 0.1 L 
Store at RT 
_ 20% EtOH 
 collected supernatants and place on ice 
 tubes) by adding 0.5 ml 1M Tris-HCl, pH 9 
onnect the column to the syringe using 
_ 5. Slowly “pump” the solution through column drop-by-drop at a rate of ~5 ml/min 
ff the syringe, remove plunger, 
lumes 
ty of ~ 25 mg human 
_ 8. Wa
__ 9. Elu lumn volumes of Glycine buffer (pH 2.7) and collect in the prepared 15 ml conical 
0C until dialysis 
 5 column volumes of 
umn 
  numerous times 
ris-HCl (pH 9) 
0 
 
- 
_
 
 
__ 1. Thaw
__ 2. Prepare collection tubes (15 ml conical
__ 3. To wash the column, fill the syringe with NaHPO4 buffer and c
the provided adaptor 
__ 4. Remove the twist-off end 
_
⇒ Important!!  To avoid introducing air into the column, twist o
reconnect it to the column, and fill with buffer 
__ 6. Wash column with ~5 column vo
__ 7. Apply the thawed supernatants, 5 ml at a time.  The column has a binding capaci
IgG/ml gel.  Therefore, ~800 ml of supernatant can be loaded onto the column before eluting.   
_ sh with ~5-6 column volumes of NaHPO4 buffer or until no material appears in the effluent 
te with ~2-5 co
tubes.   
__ 10. The eluted samples can be frozen at –8
__ 11. To continue loading more samples onto the HiTrap column, wash with
NaHPO4 buffer and proceed with steps 7-10.   
__ 12. To store the column, wash with 3 column volumes of 20% EtOH, close up both ends of col
using the provided adaptors, and store at 4C  
⇒ column can be used
 
Dialyzing, “Concentrating,” and Sterilizing Ab 
 
Lyzer Dialysis Cassettes, MWCO 10, 000, 3-12 ml (Pierce, 66810) 
ooled to 4C) (~5 L or more) 
100, 000 MWCO) 
bran (Gelman Labs, 4192) 
ace on ice 
Materials: 
__ Slide-A-
_ 1XPBS (c_
__ 20 ml syringe 
__ 18G needle 
__ Amicon Ultra-15 Centrifugal Filter Device (MilliPore, PL-100, 
fryn Mem__ Acrodisc Syringe Filter, low protein binding, 0.2µm HT Tuf
 
 
__ 1. Thaw samples and pl
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__ 2. Remove Slide-A-Lyzer cassette from its pouch and slip the longest side into the groove of a buoy 
r for ~30 sec 
ringe with needle and fill with sample 
 a syringe port at the top of the cassette 
raw back the syringe to remove the air in the pouch 
 continue inject the sample 
_ 6. Remove any air from the pouch using the syringe 
_ 7. Place membrane into 1XPBS buffer and dialyze overnight at 4C with constant gentle stirring 
 cassettes) can be dialyzed in a 5 L container of 1XPBS 
le 
Unit (up to 15 ml) 
 
__ 11. R -to-side sweeping motion with a pipetter to ensure 
 
 
 
__ 3. Immerse the cassette in 1XPBS buffe
__ 4. Attach sy
_ d sample to cassette through_ 5. Ad
 ⇒ be careful not to burst the membrane.  D
and then
_
_
⇒ As per Laurie, ~ 120 ml of sample (~10
(final Glycine concentration of sample should be < 0.0006M) 
__ 8. Remove sample from cassette by inserting the needle into the bottom syringe port and slowly 
withdrawing the samp
__ 9. Place sample in the Amicon Filter 
__ 10. Spin at 4000 x g for ~7 min at RT (use Juoan) 
⇒ volume will be ~0.5 ml at this stage 
ecover the concentrated sample by using a side
total recovery 
__ 12. Under a sterile hood, sterilize the sample using a sterile 5 ml syringe attached with 
a Acrodisc Syringe Filter (low protein binding).   
__ 13. Aliquot into sterile 0.65 ml eppendorf tubes and store at –80C. 
__ 14. Perform protein assay using Coomassie Blue  
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Immunoblot Stripping Protocol 
(from Nicole Murray, nmurray@utmb.edu) 
 
 
 Solutions: 
 1 M Tris:     Final Concentrati
 121.4 g. Tris base    1M 
on: 
 0  
 
 
 10
  
2
 n will precipitate, but should become soluble at RT) 
_   1. P re-warm to 50°C using H20 bath on “belly dancer”  
 onut” on top of dish so that it is stable in the H20 bath 
in. at RT  twice 
__  4  stripped, block membrane in 4% nonfat dry 
will be used for the next 1° antibody for at least 1 
hr. at RT  
_   6. Wash mem rane vigorously in 1XPBS/Tween for 15 min. at RT twice.  
__   7. Add substrate (Supersignal WestFemto) to membrane on acetate sheet for 5 min. 
__   8. Image blot n Fluor-S Imager to ensure that no signal is detected. 
__   9. Repeat ste 1-10 if signal is still detected. 
__   10. Once blot s properly stripped, proceed with Western Blot protocol as if you have just completed 
the membr e transfer (i.e, block membrane in milk→ incubate with 1° antibody overnight, etc.) 
 
 
 
 
 -add ~500ml. ddH20 and adjust pH to 6.7 using HCl  
-bring up to volume (1L) using ddH2
-store at 4°C    
  
 Stripping Buffer:     
To make 1L: 
6.99 ml. 2-ME (14.3 M)    100 mM 
0 ml. 20% SDS    2% 
62.5 ml. 1M Tris (pH 6.7)    62.5 mM
 -add ~200 ml. ddH20 and adjust pH to 6.7 
 -bring up to volume (1L) using ddH 0 
-store at 4°C (solutio
 
To strip membrane of its 1° and 2° antibodies: 
_ our stripping buffer in covered dish and p
__   2. Place membrane in pre-warmed stripping buffer for 30 min. with gentle rocking  
⇒ place “d
__   3. Once 30 min. are up, wash membrane vigorously in 1XPBS/Tween solution for 10 m
. . To ensure that the membrane has been properly
milk/1X PBS/0.1%Tween for 1 hr. at RT 
__   5. Incubate membrane in the secondary antibody that 
_ b
 o
ps 
 i
an
 
 After the  time, steps 4-9 can be omitted once you are convinced that this process effectively eliminates all
non-specific signals  
**
 1st
 Note  all antibodies are different so do not assume that this protocol will be effective for all antibodies 
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Materials: 
round bottom plates 
__ ste
 
 
) 
2-ME 
 
  d 3.5µl. stock 2-ME to 1 ml. RPMI 1640 
__ Fal
__ Mu
__ ste
α
you 
tock: 1000ug/ml) to 
 __   n and using a multi-petter and a sterile solution 
n, prepare all stimuli solutions 1st  
RPMI mixture with homologous mouse serum 
 -pipette solution up and down several times to ensure proper mixing and allow to sit 
for a few minutes 
H3-Thymidine Uptake  
(from Chapkin Lab, Lan Ly) 
 
 
 __ sterile 96 well-
 rile 1XPBS 
 __ Complete RPMI mixture 
 - RPMI 1640 Irvine Scientific, cat #9159 
 - 2.5% homologous sterile filtered mouse serum 
  - 2.5% heat inactivated FBS (Irvine Scientific
  - [10µM] 
  ⇒ stock 2-ME is 14.3M 
 1) ad
   2) add 100µl. of this solution to the RPMI mixture 
  * for Peyer’s Patches, add 50ug/ml Gentamicin  
 con polypropylene tubes 
 lti-petter 
 rile solution basins 
 
Plate CD3  24 hours before day of experiment: 
 __   0. Contact Shannon Sedberry (sedberry@tamu.edu) to let her know what day(s) 
will be using the harvester 
 __   1. In a sterile hood, dilute αCD3 (Pharmingen: 553057) (s
1ug/ml in sterile 1X PBS 
 __   2. Designate and label wells of a 96-well plate (CD3/28, Con A, RPMI, etc) 
3. Mix αCD 3 solution(s) once agai
basin, pipette 50µl. of αCD 3 into each well 
 __   4. Tape lid to plate and place at 4°C overnight 
 
Day of Experiment: 
*Before proceeding with T-cell purificatio
__   1. Dilute αCD28 (Pharmingen: 553294) (stock: 1000ug/ml) to 10ug/ml in complete 
 ⇒ final concentration of CD28 in plate well will be 5ug/ml because you will 
dilute this 1:2 later 
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__   2. Place all stimuli solutions in 4°C and proceed with T-cell purification and adjust 
final concentration to 2 x 106 T-cells/ml 
 
6  Complete RPMI mixture with homologous mouse 
T 
well plate  
on basin, pipette 100ul. Of CD28 solution 
(a opriate wells  
 down and using a mult-pette and a 
st ells to the labeled wells 
id to the plate and place in 37°C incubator for 72 hours 
ake sure there is a sufficient amount of H20/ BacDown in the bottom of the incubator 
re and after 3-day incubation to check 
 
 
nsure 
 
 conical tube (this will be enough for 
1 plate) 
map” by numbering each well of each plate  
  
__   5 tor that will contain a conical tube 
of 1
           ⇒ ere or not made up, consult Shannon 
 idine + 4 ml. complete RPMI 
__   1. Obtain 2 x 10  T-cells/ml. in
serum and place at R
__   2. Aspirate CD3 antibody from the 96-
__   3. Using a multipipettor and a sterile soluti
nd her stimuli) into appr/or ot
__   4. Thoroughly mix the T-cells by pipetting up and
erile solution basin, add 100µl. of the T-c
__   5. Tape the l
M
-Make sure and check cells under microscope befo
for proper proliferation 
Day 3 
 __   1. Remove plates from 37°C incubator and check cells under microscope to e
T-cells have proliferated. 
⇒ also, observe color of media  
__   2. Pipette 4 ml. of complete RPMI into a 15 ml.
__   3. Make a “plate 
           ⇒ this will be used to help keep track of the filter discs 
__   4. Bring plates, 4 ml. RPMI and multipipettor over to McMurray Lab in Med. School
. In their tissue culture room, there is a refrigera
00µCi H3 Thymidine solution 
 if solution is not th
__   6. In the radioactive hood, dilute the 100µCi H3 Thymidine 1:5 to 20µCi 
⇒ 1 ml. of H3 Thym
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 ⇒ final concentration in wells will be 4µCi H3
__   7 olution basin, add 50µl. of 
20µCi H3 Thymidine to all wells of each plate containing cells 
__   9  plate(s) downstairs (2nd floor) where cell 
__   1 ester) to approximately the size of the 
__   1
 ensure all 
__   15. Suck up contents of plate using HOT vacuum and was plate with H20 at least 7X 
_   16. Remove top compartment with vacuum on to help dry the filter 
. Once filter looks dry, remove the template with the filter still on it 
_   18. To clean the harvester, fill the bottom platform with EtOH and run EtOH through 
  off pump when finished 
ated numbers of each filter disc (see plate map) 
propriate scint vial 
rresponds to the 
__   2  to right and place a red STOP rack behind the 
       
. Using a multipetter and the radioactive s
__   8. Allow plates to incubate in 37°C incubator for 5 ½-6 hours 
. After incubation, bring
harvester is 
__  10. Turn on vacuum pump located below the Packard cell harvester 
1. Cut a filter paper (in drawer below cell harv
96-well plate 
2. Place the filter in the top compartment of the harvester 
__   13. Run H20 through the harvester using COLD and HOT vacuum to
probes are aspirating and dispensing well (~3x) 
__   14. Place the sample plate directly underneath the probes 
_
__   17
_
the harvester.   
⇒ make sure to turn
__   19. Label scint vials with the design
__   20. Using forceps, gently remove the perforated discs of filter paper and place them 
in the ap
 ⇒ remember the orientation of the plate and how it co
perforated discs (it will be reversed) 
__   20. Then fill each scint vial with 10 ml. scintillation fluid 
__   21. Bring scint vials over to the beta/gammer counter at Kleberg rm. 423 
2. Load scint vials in rack from left
last rack 
__   23. Use Counter User #1 and AutoCount 
⇒ Vials are counted for ~ 1 min. each  
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CD4 + T-CELL ISOLATION 
 
 (From the Chapkin Lab, Jennifer Arrington) 
 
I. NECROPSY 
 
 Materials: 
 __ s terile instruments (i.e. scissors, forceps, etc.) 
  __ EtOH 
l. 
 500ml. RPMI + 55 ml. FBS + 5.5 ml. L-Glut + 5.5 ml. P/S + 100µl. 
.5µl.  
2 
 you 
on 
he spleen (dark red organ) with forceps 
leen as possible  
__ a labeled 15 ml. conical tube for each mouse group filled with 3 m
complete RPMI (10% FBS, 1% L-Glutamine, 1% Pen-Strep, and 
10µM 2-ME) 
 ⇒
of 3
2-ME diluted in 1 ml. RPMI 
  __ keys for basement 
  
   
__   1.  Sacrifice mice (_________________) by CO
__   2. Place mice on their right side so that the left side faces
__   3. Apply alcohol to the abdomen area 
__   4. Grab the skin of the abdomen with forceps and make a small incisi
__   5. With fingers, peel back the skin/fur to expose the membrane underneath 
__   6. Grab the membrane with forceps and cut the membrane to expose the 
organs 
__   7. Remove t
__   8. Carefully remove as much fat from the exterior of the sp
__   9.  Place spleen(s) in a conical tube containing complete RPMI 
 
II. CELL PREPARATION 
Materials:  
  __ sterile wire filter 
  
__   1. ch spleen and RPMI solution into a glass-in-glass homogenizer  
 (~5-7 strokes) 
__   3. Assem each spleen and place on top of a 
newly l
. Remove the syringe plungers and transfer the appropriate spleen suspension into the assembled units 
  __ sterile glass-in glass homogenizers 
__ 10 cc syringes 
  __ 20 gauge needles 
  __ RPMI mixture  
  __ 15 ml. conical tubes 
 
 
 Transfer ea
__   2. Homogenize spleens until completely broken up
ble a 10 cc syringe, wire filter, and 20 gauge needle-unit for 
abeled 15 ml. conical tube  
__   4
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__   5. Slowly reinsert the sponding conical tube  
            ⇒  cells are fr
_   6. Fill each sample tube with RPMI for washing and centrifuge at 200 x g (rcf=200, rpm=1096) for 5 
m
_   7. Meanwhile, soak all used equipment in soapy H20 
e spinning, carefully aspirate the RPMI leaving only 0.5 ml. in each sample 
, etc. 
 
III. REMOVE RE  
 plunger to filter the suspension into the corre
agile, so be gentle with this step 
_
in. at RT 
_
__   8. Once samples are don
tube 
 ⇒ the lymphocytes are now ready to be isolated from the red blood cells, plasma
D BLOOD CELLS 
Materials: 
_  Lym ed to RT 
_  R&D D4+ purification kit 
 
sh buffer (diluted from 10X) (lot #_________) 
 
__   1. Add R 3 ml RPMI for 60-80 x 106 
cells, a
  ⇒ n
__   2. Add a
⇒ i pholyte-M.   
     ⇒ this s  be done slowly and carefully in order to see 2 distinct bands 
__   3. Centri
⇒  d
stop
⇒ meanwhile, begin T-cell column preparation 
 disturb sample layers when removing the samples from the centrifuge  
ne spinning, you will see 2 distinct layers (a white one on 
the bottom) and an interface band separating 
em.  Your goal is to remove this interface band.  The bottom clear layer 
contains the unwanted red blood cells, plasma, etc.   
 layer with a pipette 
__   6. d the cells in 2 ml. 1X R&D wash buffer 
 _ pholyte-M (lot #_____
_  antibody cocktail in C
____) cool
 
 __  RPMI mixture
 __  1 X column wa
PMI to the washed cells (add 2.0 ml RPMI for 30-40 x 106 cells or 
s per Chris Jolly) and resuspend 
ormally, one spleen yields 30-40 x 106 cells 
n equal amount of Lympholyte-M by layering it beneath the suspended cells 
nsert the pipet tip into the bottom of the conical tube before dispensing the Lym
tep must
fuge the cells at 500 x g (rcf=500) for 15 min. at RT 
eactivate centrifuge brake at this step (acc/dcc = 0); the centrifuge     tends to 
 too fast and this will disturb the layer produced by Lympholyte-M  
⇒ be careful not to
⇒ when samples are do
t and a clear, pinhe top k one on 
th
__   4. Carefully remove the interface band between the medium and Lympholyte-M
and dispense it into a new conical tube (should see a red pellet) 
__   5. Fill the conical tube with RPMI to wash and centrifuge the cells at 300 x g for 5 min. at RT 
 Aspirate off the RPMI and resuspen
__   7. Add 1 vial of monoclonal antibody cocktail (1 ml) to suspension and mix gently 
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__   8. Allow cells to incubate at RT for 15 min. 
__   9. Wash cells in 10 ml. 1X column buffer and spin at 300 x g for 10 min. 
__   11. Resuspend final cell pellet in 2 ml. 1X column buffer 
IV. T-  PURIFICATION 
aterial
_ R&D CD4+ T-cell columns (Cat# MCD43; 2spleens minimum on each column) (lot#__________) at RT 
 ml conical tubes 
_ waste
_ timer
_ 1 X c __) (make 75ml. per column) 
_ RPM
column FIRST to avoid drawing air into the 
__   3. A
 EtOH 
__   4. W
__   5. R
__   6. App lumn 
⇒  in 
the sterile c
__   7. A
__   8. A
__   9. Once all the T-cells have been collected (the column will stop dripping), 
centrifuge them at 300 x g for 5 min. at RT 
__   10. Aspirate off the supernatant and resuspend in 1 ml. complete RPMI 
__   10. Decant supernatant and repeat step 9.  Decant. 
  
 
CELL
M s: 
_
__ R&D column rack 
__ 70% EtOH 
__ sterile 15
_  receptacle 
_ (s) 
ted from 10X) (lot#__________ olumn wash buffer (dilu
_ I mixture 
  
__   1. Place the T-cell column(s) in the R&D column rack and place a waste receptacle directly beneath the 
column(s) 
__   2. To prepare the columns, remove the top cap of  the 
bottom of the column and then remove the bottom cap 
llow the fluid within the column to drain until it reaches the level of the top white filter 
 ⇒ column will stop dripping once it reaches the top filter 
 ⇒ meanwhile, rinse the outside of the column tip with 70%
ash column with 10ml. of  1X column wash buffer 
eplace the waste receptacle with a newly labeled 15 ml conical tube 
ly the 2 ml cell suspension to the top of the co
 the cells will enter the column and displace the wash buffer in the column, which is collected
onical tube 
llow the cells to sit within the column for 10 min. at RT 
pply 10ml. of 1X column wash buffer to the column to elute the T-cells 
⇒ the cells are now ready to be counted.  You will determine the percentage of live vs. dead cells 
and obtain a percentage of viability 
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V. TRYPAN BLUE EXCLUSION or COULTER COUNTER 
 cell counter 
e to the empty sample tubes 
e well by pipetting up and down several times 
ixture and plate in a hemacytometer 
 immediately after the cells have mixed with the Trypan Blue because Trypan Blue 
able white cells (dead cells appear blue) in at least 4 squares of the grid 
#1_______       #2_______      #3________      #4________     Total_______ 
 cells) x 10,000 x (dilution factor=20)= # cells/ml. =__________________________ 
***Fro cedure, this cell count (in step #6) should be 
**Thi
 
 
 
 
 
 
 
Materials: 
__ Trypan blue  
__ small sample tubes 
__ hemacytometer 
__
 
 
190µl. of Trypan Blu__   1. Add 
__   2. Swirl the suspended T-cells and remove 10µl. and add them to a sample tube with Trypan Blue 
__   3. Mix this mixtur
__   4. Remove 10µl. of this m
 ⇒ do this step
kills cells after long exposure 
__   5. Count the vi
 
__   6. The # of cells will be the average of the 4 squares : Avg._____  
⇒ (Avg. #  
 
m the cell count obtained prior to T-cell purification pro
~30% less) as per Jennifer Arrington. 
* s CD4+ T-cell purification yields ~4-5x 106 cells/spleen 
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WESTERN BLOT 
Solutions: 
Pyronin 5X Sample Buffer: 
ol)   
se, pH 6.8 (Roche 604 203) 
5% β-mercaptoethanol (wt) (Sigma M-6250) 
0 mM EDTA (Sigma ED4SS) 
. Heat
. Add
5. Add
. Aliq  rest at –20°C 
ilute 
1. Add ris-Glycine (Fisher, cat #BP1306-1 or GeneMATE, cat# 
 2
 
(0.1% (wt) Tween-20 in 1X PBS) 
ttle of Dulbecco’s Phosphate –Buffered Saline (Gibco, #21600-069) in 1L. of H20 
. Add 10 g. of Tween-20 (Fisher, #BP337-500) 
         ⇒ weigh the PBS/Tween on the scale while adding the Tween-20 
. Dilute the 10X PBS/Tween using H20 to make a 1X solution 
aterials: 
__ 10-0.6 ml. eppendorf tubes  
 H20  
__ Standard (_______________)  
__ 4-12% Tris-Glycine gel (Novex, EC-6025)   
__ Electrophoresis unit 
__ 2 small staining trays 
__ 1 large staining tray 
__ wet transfer membrane (Millipore Immobilon-P Transfer, #IPVH00010) 
__ Transfer cassette 
__ stir bar 
 stir plate 
__ 6 mm filter paper (Midwest Scientific, #6MW10X11) 
__ non-fat dry milk 
PBS/Tween 
 __ test tube 
Materials: 
40% glycerol (v
.31 M Tris Ba0
2
2
12% SDS (wt) (Fisher BP166-100) 
0.1% pyronin Y (wt) (Bio-Rad 16+0425) 
 
1. Add 1.5 g. of Tris base in 10 ml. of H20 
    Actual pH____ 
2. Add 4.8 g. of SDS and bring final volume up to 15 ml. with H20 
3  gently to dissolve or leave at RT overnight 
4  8.9 ml. of β-mercaptoethanol (stock =1.2 g/ml) 
 16 ml. of glycerol 
6. Add 0.37 g. of Na4EDTA 
7. Add 0.04 g. or less of pyronin and let stir at RT to dissolve 
8 uot solutions into eppendorf tubes.  Keep one at RT for current uses and store
 
Running Buffer: (Tricine SDS Running Buffer) 
the 10X Tricine SDS running buffer (Novex, #LC1675) to 1X using H20.  Store at 4°C D
 
Transfer Buffer: (Tris-Glycine Transfer Buffer) 
To make 1L: 
 140 ml. of MeOH to 100 ml. of 10X T
5560) 
2. Bring up to volume with H 0.  Store at 4°C 
PBS/Tween: 
1. Dissolve 1 bo
2
  
3
 
 
 
M
 
 __
 
 
 
 
 
 
 
 
 __
 
 
 __ 
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 __ transfer unit 
 __ antibodies (_________ ___________) 
 __ chemiluminescent super signal reagent A and reagent B (Super Signal Substrate West 
mum Sensitivity Substrate, Pierce, #99030170) 
________________________
Femto Maxi
 
 
Day 1 
 
I. GEL LOADING 
 
 __   1. Calculate the amounts needed on the Western worksheet for sample, water, and pyronin 5X 
_   2. Pipette the samples, water, and dye into 0.6 ml. eppendorf tubes labeled 1-10  
d by a quick spin in a minifuge 
tside positions tend to heat up unevenly 
inifuge to get all the condensation to the bottom of the tube 
is unit: 
rom the precast gel 
it (if only 1 gel is used, put an alumina plate to block 
_ ansfer the unit into 4°C cold room and pour running buffer into the unit 
 the gels 
ell 
(red to red and black to black) 
⇒ set voltage higher than the mAmp setting 
 check the gel the 1st 5 min. and then 20 min. thereafter 
⇒  the current between 60-120 mAmp 
the gel, turn off the power supply and take the unit out  
the col
. BLOT
_
  mix by⇒  gentle inversion followe
__   3. Heat samples at 98°C in a Thermal Reactor for 5-10 min. 
 ⇒ place samples in middle of heat rack; the ou
__   4. Quick spin on the m
__   5. Place the 4-12% Tris-Glycine gel onto the electrophores
 ⇒ mark the position of the wells with a sharpie pen and label them 1-10 
 ⇒ take off the tape and remove the comb f
 ⇒ align the 3rd grid onto the gasket of the unit 
 ⇒ use 2 clamps to fasten the gel onto the un
the other side of the unit) 
_   6. Tr
 ⇒ make sure to fill the space between
__   7. Load samples into the corresponding wells 
 ⇒ make sure there is no bubble in the pipette tip when dispensing the sample into the gel w
__   8. Place the lid on the electrophoresis unit and connect the electrodes 
__   9. Run gel at 30-60 mAmps for ~1 hour 
 
 ⇒
  if 2 gels are running together, set
__   10. Once the dye approaches the bottom of of
d room to sit beside the sink 
 
II  
_   1. Pour t
he gel from the unit; place the gel on the bench (large side down): 
use a s
 the 1st lane; cut and remove the area below the bottom dye band 
_ ransfer buffer into a clean staining tray 
_ ve the 2 clam_   2. Remo ps to loosen t
patula to unseal the plates; carefully remove the gel 
_ a cut above the gel ju_   3. Make st above
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__   4. Gently transfer the gel from the cast (grab the gel from the bottom area) to the staining tray 
co tai
 ⇒ place th
_   5. Wet the transfer membrane with MeOH for a few seconds in a separate staining tray 
ransfer the membrane into the staining tray containing the transfer buffer 
sfer cassette into a big staining tray (gray side up): open the cassette and place the thick 
sponge on the bottom (black colored grid) and then the thin sponge on the top (gray colored grid) 
_   9. W  thick sponge 
ight side) 
_   11. ubbles 
ne as well; again, 
_   13. h sides  
_   14. cing the labeled “black side’) 
_   15. 
         ⇒
          ⇒ re te by gently dropping the unit on the counter 
_   17. T fat dry milk/1X PBS/0.1%Tween in a staining tray 
_   18. A
y (gray side up).  Open the cassette, remove the thick sponge 
an  on the membrane; cut a corner above lane #1 
onds until protein bands 
 k into container (solution is re-usable) 
  to blot and swirl briefly. Repeat. 
d. leave blot in Destain solution and image 
⇒ use large lens (set at 2.7 at top aperture to let light in) 
⇒ place blot in bottom of machine (make sure tray is not in machine) 
uor-S → Select→ Densitometry→ Photograph 
 p aperture from 2.7 to 22 
 ⇒ save image on disk and print 
  e. rinse blot briefly in PBS (until blot no longer smells like MeOH) 
n ning the transfer buffer 
e gel the same side up as taken from the cast 
_
__   6. T
__   7. Place the tran
__   8. Pour the transfer buffer to cover the thick sponge 
 ⇒ pour a little extra in to cover the gel and membrane later 
_ et a 6 mm. filter paper with transfer buffer; place the paper onto the
__   10. Place the gel onto the filter (same side up; lane #1 is the r
_ Place the wet membrane onto the gel and use the side of a glass test tube to roll out any b
__   12. Wet another 6 mm. filter paper in the transfer buffer and place it on the membra
roll out any bubbles with a glass test tube 
_ Place the sponge onto the filter paper and close the transfer cassette on bot
_ Immediately, put the cassette into the transfer unit (black side fa
_ Fill the unit with transfer buffer with a stir bar 
   transfer the unit to the 4°C cold room 
lease any air bubbles in the casset
__   16. Place the unit on a stir plate and run at 400 mAmp for 90 min. 
_ owards the end of the transfer, prepare 4% non
(1.2 g. milk in 30 ml. PBS/Tween) 
_ fter transfer has completed, take the unit out of the cold room and place it near the sink 
__   19. Remove the transfer cassette from the unit using the hook attached to the outside of the unit 
__   20. Place the cassette in a big staining tra
d filter paper; use a pencil to label lanes #1-10
FAST GREEN STAIN (optional): 
 a. place blot in fast green stain solution and swirl for a few sec
are seen 
b. then dump solution bac
c. add Destain solution
 
 
 
 ⇒ select Quality One→File→Fl
 ⇒ with both lens and main door open, Position and Focus the blot without holding 
down the SHIFT key  
⇒ after blot is positioned and focused, turn to
 ⇒ close both doors and Acquire image for 10 sec. 
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 f. Proceed to step 21 as usual 
⇒ milk will turn
. Transfer the membrane into a
  green, so replace solution ½ way through blocking 
__   21  staining tray containing 4% nonfat dry milk/1X PBS/0.1%Tween 
S/0.1%Tween (0.8 g. 
__   24 d 
_   25 ake gently in the cold room 
0 ml. of 4% nonfat dry milk/1X PBS/0.1%Tween 
ur into a staining tray 
ondary antibody 
__   7. ontaining PBS/Tween for a few seconds 
__   11 orf 
_   12. Lift the top 
lane#1 on left s
_   13. Gently lowe w it to incubate for 
15 min. 
_   14. Cut out a ne
⇒ pip o that 
the me
_   15. Visualize th
hield 
⇒ make sure membrane is protein side up 
__   22. Gently shake for at least 1 hour at RT 
__   23. Towards the end of the hour, prepare 20 ml. of 4% nonfat dry milk/1X PB
milk in 20 ml. PBS/Tween) and place in a staining tray 
. Before adding the transfer membrane, add ____µl. of primary antibody (_________) to the tray an
swirl to mix 
_ . Transfer the transfer membrane to the antibody mixture and sh
overnight 
 
Day 2 
__   1. Remove the tray from the cold room and transfer the membrane into another tray containing 
PBS/Tween for a few seconds 
__   2. Pour off the PBS/Tween and add new PBS/Tween.  Shake vigorously for 10 min. 
__   3. Repeat step 2. 
__   4. Towards the end of the last 10 minutes, prepare 3
(1.2 g. milk in 30 ml. PBS/Tween) and po
__   5. Before adding the transfer membrane to the nonfat milk mixture, add ____ µl. of sec
(______________) into the tray and swirl to mix 
__   6. Gently shake for at least 1 hour 
 Transfer the membrane into a tray c
__   8. Pour off the PBS/Tween and add new PBS/Tween and shake vigorously for 15 min. 
__   9. Repeat step 8 
__   10. Drain the membrane and place it between an acetate sheet 
. Mix 0.5 ml. of chemiluminescent super signal reagent A and 0.5 ml. of reagent B in an eppend
tube 
_ acetate sheet and add the super signal reagent mix to the top of the membrane (position 
ide) 
_ r the acetate sheet back to cover the membrane/reagent mix.  Allo
_ w acetate sheet and place the membrane between the new sheet 
 ette up the supersignal from the wet sheet and add a drop or two to the dry sheet s
mbrane does not dry out too much   
_ e membrane on Fluor-S machine: 
 a. Open the top compartment and raise the bottom s
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 b. Pull out the tray under the shield and place the membrane in the center (right side 
 →Fluor-S 
embrane so that the image will be centered 
 ield 
 
 
 of 
up) 
c. Click on Quality One icon and select File
 d. Position and focus the m
 e. From bar menu, select Blot→Chemilluminescent→High Resolution 
f. Close the top compartment and lower the sh
 g. Enter an appropriate time session (usually 480 seconds) and Retrieve 
Note: An immunoblot is a 3-step process used to separate proteins and then identify a specific protein
intere tep separates the protein mixture on a polyacrylamide gel.  The proteins are then blotted 
onto a ose membrane, which binds proteins tenaciously.  The membrane is soaked in a 1° Ab 
lution specific for the protein of interest.  The membrane is then developed in a solution containing a 2° 
 binds to the 1° Ab-coated protein to form a “sandwich” of Ab molecules.  The 2nd Ab is covalently 
dded 
 
 
 
 
 
 
 
 
 
st.  The 1st s
nitrocellul
so
Ab that
linked to an alkaline phosphatase, which catalyzes a chromogenic reaction.  Finally, a substrate is a
and a deep purple precipitate forms, marking the band containing the desired protein. 
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FLOW 
EXPRESSION 
_ arrange procedur ch Bldg, Room 
114) 
aterials: 
_mouse αCD16/CD32 (Pharmingen, cat #01241D, 0.5mg/ml) 
 use 1 µl. of stock solution/ 1 x 106 cells 
tore at 4°C 
_ACK lysis buffer (from Handbook of Flow Cytometry Methods, pg. 145) 
. To make a 10X stock solution:  2. To make working 1X lyse solution: 
.2 g. NH4Cl     Dilute 1:10 (10 ml. stock + 90 ml. dH20 
.84 g. NaHCO3  
.37 g. EDTA    
ring up to volume with dH20 (100 ml. ) 
tore at 4°C for up to 6 months. 
_ Fluorescent IL-10R Ab, Pharmingen (PE) #559914); CD28-PE, Pharmingen (#553297), CTLA-4-PE, 
harmingen (#553720) 
 dilute cell Ab 1:10 (→ 20µg/ml) in wash buffer (PBS + 0.5% BSA + 0.1% NaN3)    
_ Fluorescent Isotype control (PE) (Pharmingen #554685) 
_ Quantibrite Beads (PE) Becton-Dickinson # 340495 
_   1. Resuspend cells = 2 x 106/ml. in RPMI 
_   2. Place 500µl. (or 1 x 106 cells) into each of pre-labeled 1.65 ml. tubes  
(total of 30 tubes per culture time (3 diets x 5 mice/group x 2 mouse species) 
⇒ make sure to include controls  
• Only 7-AAD 
• Only PE 
• Isotype control 
_   3. Add 1µl. of 0.5 mg/ml of αCD16/CD32 to the cells.  Gently vortex 
⇒ this process blocks the Fc receptors, which prevents nonspecific binding of the fluorescent Ab to 
the cells.  This eliminates false positive signals 
_   4. Allow the cells to sit for 10 min. at RT  
⇒ meanwhile, spin IL-10R and Isotype Ab tube at 16,000 x g for 20 min. @4°C to pellet aggregates 
__   5. Add 20µl. of 7-AAD to each sample.  Vortex gently and allow to incubate in dark at RT for 10 min. 
  ⇒ these samples can no longer be fixed with paraformaldehyde 
CYTOMETRY FOR CELL SURFACE RECEPTOR 
(from the Chapkin Lab, Lan Ly) 
 
 
_ e with Dr. Roger Smith (rosmith@cvm.tamu.edu) 845-3293; Vet Resear
 
M
 _
⇒
__7-AAD viability probe (Pharmingen, cat #555816) 
⇒ use 20 µl of stock solution/ 1 x 106 cells 
__Wash Buffer (1 XPBS + 0.5% BSA + 0.1% NaN3, pH 7.4) (for BSA, use fraction-free #100030 or 
100018 (different size) from Boehringer Mannheim) 
0.5 g. BSA  (sprinkle on top and wait for it to dissolve, do not try to stir) 
0.1 g. NaN3
Bring up to volume with PBS (100 ml) 
S
_
1
8
0
0
B
S
_
P
a.
_
_
 
_
_
 
_
 
_
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__   6. D
• 1:10 (20µg/ml) ⇒ 360µl. Ab otal of 7200ul.) 
_   7. Dilute fluorescent Isotype control Ab (stock: 200ug/ml) in wash buffer 
_   200µl. of diluted fluorescent IL-10R or Isotype control Ab to appropriate tube except “control”. 
 (Final Ab conc._4µg_) 
oil) for 30 min. at RT 
buffer from 10X 
.  Remove all but 100 µl. of supernatant 
 the 
 min. at RT.  Decant.  
bes with wash buffer and repeat step 12.   
 PE beads b  adding .5 ml. w
alues f lot #_________: 
 Mean # of PE molecules/bead 
Low  ____________ 
Med-High  _____________ 
 for analysis 
 
 in each tube and thus, the 
ilute fluorescent IL-10R Ab (stock: 200µg/ml) in wash buffer: 
 + 3240µl. wash buffer x2 (for a t
 _
• 1:10 (20ug/ml) ⇒ 30ul. Ab + 270ul. Wash buffer x2 (for a total of 600ul) 
8. Add _
Gently vortex
__   9. Allow cells to incubate in the dark (wrapped in aluminum f
 ⇒ meanwhile, prepare 1X ACK lysis 
__   10. Spin cells at 300 x g for 5 min. at RT
__   11. Add 1ml. of 1X ACK lysis buffer to lyse RBCs.  Gently vortex and allow to incubate at RT, in
dark, for 10 min. 
__   12. Spin cells down at 300 x g for 5
__   13. Fill tu
__   14. Fill tubes with 300 µl. wa  sh buffer 
__   15 Prepare y  0 ash buffer to tube and gently vortex: 
   V or 
                                               Bead level 
    
   Med-Low  ____________ 
   
    High  _____________ 
__   16. Wrap samples in foil and submit to Dr. Roger Smith
• bring zip disk to copy results file 
 
 
Notes: The flow cytometer will give the percentage of cells conjugated to FITC
percentage of each cell type. 
FACS on the light scattering 
roper cell types.  Gates are set by the technician.  A cell that binds a 
bele t does not, will not.  A histogram will show that the non-T-cells 
prod e o the left while the labeled T-cells produce a peak shifted to the right. 
 
gates (the cells that the flow cytometer actually counts for analysis) are based 
p ties which are inherent in specific 
la d Ab will fluoresce whereas one tha
uc a peak shifted t
 
   
  133 
IL-10 ko Mouse Genotyping 
__   
__   easy
__   Pl 306-016) 
__   St  #1044-01-9) 
   4% N 927) 
_   Scal
Tail sn
(Chapkin Lab, Lan Ly) 
 
Materials: 
Silver nitrate applicator (Grafco #1590) 
DN  Kit (Qiagen # 69504) 
__   PCR primers (IL10T1.4 (87), IL10AS (86), and NEO5 (88) 
atinum PCR Supermix (Invitrogen #11
rip-Ease PCR tubes (Robbins Scientific
__   0.5X TBE Buffer (for EtBr gels) 
__ uSieve 3:1 Plus agarose gel (1X TBE Buffer + EtBr) (Reliant # 54
_ pel, forceps 
__   microcentrifuge tubes 
__   LN2 
 
ips 
 Using a scalpel, sn__   1. ip ~0.5cm. of the mouse tail  
sh freeze in LN2 
is 
ld for ~20 sec until no bleeding has stopped)  
__   2. Place the tail into a labelled microcentrifuge tube and fla
 ⇒ sample can be stored at -80°C for later analys
__   3. Seal the mouse’s tail by applying silver nitrate (ho
 
DNA isolation  
__   1. Pre-heat a shaking water bath (Belly Dancer) to 55°C (use thermometer) 
__   2. Allow samples to come to room temperature 
__   3. Follow the DNeasy protocol for ro t tden ails  from the DNeasy Qiagen kit 
 ⇒ make sure to keep everything RNase Free! 
__   4. DNA samples can be stored at -80°C or proceed with PCR 
 
PCR (keep everything RNase Free) (perform in PCR hood) 
__   1. Label PCR tubes for each sample (make sure to include positive an
__   tinum Supermix into each tub
d negative controls) 
e 
e tubes 
pe samples, pipet… 
  0.4µl  86 primer (5’-GTG GGT GCA GTT GTC TTC CCG-3’) (24 bp; IL-10T 2.2 anti-sense IL-10 
__   6. Cap PCR tubes tightly using the capping tool 
__   7. Briefly spin tubes down  
__   8. Run PCR reaction (GeneAmp PCR System) 
 Program: User→ Lan→Tails (~20min) 
 Once 20min is over for this program, immediately start Tails2 (~1hr) 
 Samples can be stored at 4°C  
Southern Blot 
2. For 50µl.. reaction, pipet 45µl of Pla
NA sample to appropriat__   3. Add 2µl. D
__   4. For wild-ty

primer) 
 0.8µl. 87 primer (5’-GCC TTC AGT ATA AAA GGG GGA CC-3’) (23 bp; IL-10T 1.4 anti-sense IL-
10 primer  
__   5. For knock-out samples, add… 
 0.8µl  87 primer 
 0.4µl  88 primer (5’-CCT GCG TGC AAT CCA TCT TG-3’) (20 bp; IL-10 KO NEO 5 anti-sense 
strand 

 
(keep everything Rnase Free!) 
__   1. For each sample, pipet 10µl sample + 1.1µl dye (10 X TAE) in a microcentrifuge tube 
 Include a ladder (Hyperladder IV (Bioline, 100-1000bp): 2µl ladder + 6µl H20 + 2µl 5X loading 
buffer) 
__   2. Spin tubes down briefly
  
  134 
 
__   3. Heat samples to 65°C for 5min in heating block 
 ⇒ in the meantime, set up gel 
• Position 4% NuSieve EtBr agarose gel in gel nit (stored in walk-in freezer) 
r gel with 0.5X TBE buffer 
gel wells 
d run gel for ~40min. 
lluminator (UV lamp) 
 
 u
• Cove
__   4. Spin tubes down briefly 
__   5. Carefully pipet samples into 
__   6. Set power source at 200V (for lid, red plug is at bottom) an
__   7. Take gel out of plastic mold and image on Transi
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